

AD _____

Award Number: DAMD17-01-1-0592

TITLE: Mechanism of Ras Activation by TGF β

PRINCIPAL INVESTIGATOR: Kathleen M. Mulder, Ph.D.

CONTRACTING ORGANIZATION: The Pennsylvania State University
Hershey, Pennsylvania 17033

REPORT DATE: July 2003

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20040112 136

REPORT DOCUMENTATION PAGEForm Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE July 2003	3. REPORT TYPE AND DATES COVERED Final (1 Jul 2001 - 30 Jun 2003)	
4. TITLE AND SUBTITLE Mechanism of Ras Activation by TGF β			5. FUNDING NUMBERS DAMD17-01-1-0592	
6. AUTHOR(S) Kathleen M. Mulder, Ph.D.				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) The Pennsylvania State University Hershey, Pennsylvania 17033 <i>E-Mail:</i> kmm15@psu.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited				12b. DISTRIBUTION CODE
13. ABSTRACT (Maximum 200 Words) Transforming growth factor β (TGF β) is a potent growth inhibitor for epithelial cells, often displaying tumor-suppressor activity. As described in our last Progress Report we have identified km23 as a novel TGF β receptor-interacting protein. Here we show that km23 is ubiquitously expressed in human tissues and that cell-type specific differences in endogenous km23 is TGF β -dependent. Further, the kinase activity of both TGF β receptors appears to play a role in TGF β -mediated phosphorylation of km23. Subcellular fractionation analyses revealed that km23 is a cytoplasmic protein. In addition, immunofluorescence analyses indicate that km23 is colocalized with the TGF β signaling component Smad2, either in the absence of TGF β treatment, or during early time periods after its addition. km23 also interacted with Smad2 in glutathione-S-transferase (GST) pull-down and immunoprecipitation (IP)/blot assays. Blockade of km23 using small interfering RNA (siRNA) significantly decreased the ability of TGF β to inhibit thymidine incorporation. Our findings suggest that km23 is necessary, but not sufficient, for TGF β -mediated inhibition of DNA synthesis. The data also indicate that km23 is co-localized with TGF β signaling components shortly after TGF β stimulation, but prior to translocation of the signaling complexes to the nucleus.				
14. SUBJECT TERMS TGF β , Src, signal transduction, GEF or guanine nucleotide exchange factor, dynein, Mapk, Ras				15. NUMBER OF PAGES 87
				16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	5
Reportable Outcomes.....	6
Conclusions.....	7
References.....	8
Appendices.....	9

INTRODUCTION:

We previously demonstrated that TGF β rapidly activates Ras (3-6 min), as well as both the Erk and Sapk/JNK Mapk's (within 5-10 min). These effects occurred in untransformed epithelial cells and in human breast cancer cells (BCCs) that had retained TGF β responsiveness in terms of TGF β 's growth inhibitory effects. Since TGF β receptors are serine/threonine kinases, the mechanisms for activation of Ras by TGF β would differ from those observed for tyrosine kinase receptors. Signaling components with SH2 domains would not be expected to directly bind TGF β receptors. The objective of the current proposal was to identify TGF β signaling components that may regulate the activation of Ras/Mapk/JNK pathways by TGF β . These studies are highly relevant to BC, since TGF β proteins are the major endogenous growth inhibitors secreted by human BCCs. More advanced BCCs lose responsiveness to TGF β 's growth inhibitory effects. This is largely mediated by alterations in TGF β signaling pathways, such as those under study in this proposal. Elucidation of the diverse signals that are activated by TGF β will facilitate our understanding of the mechanisms by which this important growth inhibitor mediates its effects, as well as how these signaling pathways are subverted to produce malignant breast cancer.

BODY:

In the last Progress Report, we indicated that we had identified km23 as a TGF β receptor-interacting protein that was also a light chain of the molecular motor protein dynein. We reported that TGF β stimulated not only the phosphorylation of km23, but also the recruitment of km23 to the dynein intermediate chain (DIC). Recruitment of dynein light chains (DLCs) to the dynein complex is important not only for specifying the cargo that will bind (*Vaughan and Vallee, 1995*), but also for the regulation of intracellular transport itself (*Karcher et al, 2002*). Thus, km23 appeared to function as a motor receptor, linking the dynein motor to specific signaling complexes contained within intracellular vesicular compartments. We also demonstrated that km23 mediated specific TGF β responses, including JNK activation, c-Jun phosphorylation, and growth inhibition. This work is now published in *MBC (Tang et al, 2002)*.

Since the binding of km23 to the DIC after TGF β receptor activation is important for specifying the nature of the vesicular contents (i.e., TGF β signaling components) that will be transported along the microtubules (MTs) (*Jin et al, 2003*), any disruption in km23 would be expected to prevent or alter movement of such cargo along MT's. In this way, alterations in km23 result in a mis-localization of these proteins, with a disruption of TGF β growth inhibitory signals. Accordingly, sequence alterations at specific regions of km23 in human tumors appear to play a role in tumor development or progression (*Ding et al, 2003; Mulder 2003; Ding and Mulder 2004*). During this project period, we have determined that one out of two human breast carcinomas from patients contained km23 alterations (see Table 1). Thus, we have novel data implicating km23 alterations in the development or progression of breast cancer. In addition, we have found several other types of alterations in km23 in human breast tumor sequences in the NCBI database (see Table 2). This indicates that a larger samples size would permit us to detect additional alterations in km23 in human breast cancers from patients. However, since the funds have been expended, we will not be able to proceed with these studies.

Since the last Progress Report, we have also completed studies to address both Objectives 1 and 2. Regarding Objective 1, we have determined that Src does not directly interact with the TGF β receptors (Fig. 1). However, instead, it appears that Src and/or its family members may be in an adaptor complex with other TGF β signaling intermediates. These other signaling components, which include km23, appear to function as adaptors to link the receptors to the direct activators of Ras during endocytosis and early trafficking events. As an example of one of these, we have shown that expression of km23 can induce the interaction of Src with the adaptor kinase Grk2 (Fig. 2). Grk2 has been shown to regulate the Ras/Mapk pathways through its association with Src, the two proteins often linked by an additional adaptor protein (i.e., *Wan et al, 2003*). In addition, previous results have indicated that another DLC, Tctex-1, can interact with the Src family member fyn (*Campbell et al, 1998*). Thus, it seems likely that the DLC we have identified, km23, might also interact with a Src family member. This may occur indirectly through the interaction of Src with Grk2 (Fig. 2), or directly. Future studies will be required to address this possibility. However, our results do suggest that Src may be involved in TGF β activation of the Ras/Mapk pathways, although we did not detect a direct interaction between the receptors and Src. The key is that adaptor complexes containing components such as Grk2, and km23 are required.

With regard to Objective 2, we could not detect a specific, TGF β -inducible change in the guanine nucleotide exchange factors (GEFs) Sos or GRF. However, there are several other GEFs that have been identified since we have submitted this application. It may well be that one of these GEFs plays a more important role in the activation of Ras or Ras family members by TGF β . For example, it has been shown that the TGF β activation of the Ras superfamily member RhoA can involve the GEF NET1 (*Shen et al, 2001*). In addition, a new GEF of the Vav family has been identified (Vav3), and shown to be regulated by TGF β (*Trenkle et al, 2000*). Since the funds have been expended, studies involving these other GEFs are beyond the scope of the current project. However, we feel that the findings we obtained from Objective 1, regarding the important role of these adaptor complexes in Ras activation, as well as the results we obtained regarding the role of km23 alterations in breast cancer development or progression, are highly significant and important outcomes that resulted from the current award.

KEY RESEARCH ACCOMPLISHMENTS:

- We have extensive functional data to demonstrate that km23 is an important component of TGF β signaling pathways such as Ras/JNK.
- We also have functional data to indicate that km23 is an important component of the cell's motor machinery, responsible for moving TGF β signaling components to their appropriate destinations in the cell.
- Expression of km23 induces the interaction of Src with Grk2, forming an adaptor complex critical for the activation of components such as Ras and Mapks
- km23 alterations occur in human breast cancer at specific sites that are critical

for the cellular functions of km23. The alterations appear to occur at a high frequency in human breast cancer.

- We have validated km23 as a critical anti-cancer therapeutic target using siRNA approaches.

REPORTABLE OUTCOMES:

Tang Q, Staub C, Gao G, Jin Q, Wang Z, Ding W, Aurigemma R, Mulder KM. A novel TGF β receptor-interacting protein that is also a light chain of the motor protein dynein. *Mol. Biol. Cell* 13:4484-4496, 2002.

Yue J, Sun B, Liu G, Mulder KM. Requirement of TGF β receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/Stress-activated protein kinases (Sapks) for TGF β up-regulation of the urokinase-type plasminogen activator receptor. *J Cell Physiol.*, Submitted, 2003.

Jin Q, Staub CM, Tang Q, Ding W, Gao G, Mulder KM. Role of km23 co-localized and interacted with Smad2 in TGF β -mediated effects. *J. Cell Sci.*, Submitted, 2003.

Mulder KM. A new target for the development of anti-cancer diagnostics and therapeutics. *Amer. Clin. Lab.*, in preparation, 2003.

Ding W, Charboneau L, Espina V, Liotta LA, Mulder KM. A TGF β receptor-interacting protein frequently mutated in epithelial ovarian cancer. *Cancer Res.*, in preparation, 2003.

Ding W, Mulder KM. Targeting km23 in human cancers. In *Molecular Targeting and Signaling Transduction: Molecular Therapeutics*. Ed. Kumar, R. Kluwer Academic Publishers, Cancer Treatment and Research Book Series, in preparation, 2004.

Mulder KM. km23: A novel target for the development of anti-cancer therapeutics and diagnostics. *Protein-Protein Interaction*, Newark, NJ, November 4-6, 2002.

Mulder KM. A novel TGF β receptor-interacting protein altered in human cancers that is also a light chain of the motor protein dynein. *TGF β Superfamily: Roles in the Pathogenesis of Cancer and Other Diseases*, La Jolla, CA, January 15-19, 2003.

Jin Q, Ding W, Staub CM, Gao G, Tang Q, Mulder KM. A TGF- β receptor-interacting protein frequently mutated in epithelial ovarian cancer. *AACR Annual Meeting*, Washington, DC, July 2003.

Jin Q, MD, Ding W, MD, PhD, Staub CM, Gao G, MD, Mulder KM, PhD. A novel target for the development of anti-cancer diagnostics and therapeutics. *Innoventure 2003*, Hershey, PA, May 2, 2003.

Invited Speaker, Presentation at the University of Texas, San Antonio, TX, 2003.

Invited Speaker, Presentation at the AACR Annual Meeting, Toronto, CA, 2003.

Press Release – *Penn State Newswire* – Study finds new target for development of anti-cancer drugs, September 4, 2002.

Press Release – *Penn State College of Medicine News Release* – Study finds new target for development of anti-cancer drugs: Protein found effective in nearly half of human cancer tissues, September 4, 2002.

Press Release – *Hummelstown Sun* – Anti-Cancer Target, September 11, 2002.

Press Release – *Espicom Business Intelligence* – New target for anticancer therapies identified, September 12, 2002.

Press Release – *Central Penn Business Journal* – Help for Cancer, September 27, 2002.

Funding Received – Based on Work Supported by this Award: Department of Defense, Idea Award, “*Development of km23-based Diagnostics and Therapeutics*”, Principal Investigator, Kathleen M. Mulder, \$526,875, 04/15/03-04/14/06.

Funding Received – Based on Work Supported by this Award: National Cancer Institute, 1 R01 CA100239-01, “*Role of km23 in Ovarian Cancer*”, Principal Investigator, Kathleen M. Mulder, \$1,250,000, 04/01/03-03/31/08.

Funding Applied for based on work supported by this award: National Institutes of Health Structural Studies Supplement, “*High-Resolution NMR Structure of km23 Proteins*”, Principal Investigator, Kathleen M. Mulder, \$40,000, 11/01/03-10/31/04.

Funding Applied for based on work supported by this award: Equipment Supplement, “*Tumor-Host Interactions*”, Principal Investigator, Kathleen M. Mulder, \$500,000, 09/01/03-08/31/04.

CONCLUSIONS:

1. The TGF β receptors do not appear to directly interact with Src (Fig. 1).
2. km23 can function as a motor receptor to link TGF β signaling components (i.e., Src, GEF, Ras, JNKs, Smads) to the motor machinery for their movement along microtubules to their appropriate sites of action (Tang et al, 2002; Mulder, 2003; Ding and Mulder, 2004).
3. km23 is co-localized with Smad2 at early time points after TGF β addition, prior to Smad translocation to the nucleus (Jin et al, 2003).
4. km23 can directly interact with the TGF β signaling component Smad2 by two different methods (Jin et al, 2003).

-
5. Blockade of km23 expression using small interfering RNA (siRNA) results in a reduction in the ability of TGF β to inhibit cell growth and to induce fibronectin expression. Both of these TGF β responses partially require Ras and Mapks such as JNK (Jin et al, 2003).
 6. Alterations in km23 in human breast cancer have been identified in one out of two patients thus far.
 7. Alterations in km23 can reduce its ability to interact with the dynein motor complex, thereby limiting the ability of TGF β signaling components (i.e., Src, GEFs, Ras, JNKs, Smads) to function in the appropriate manner (Jin et al, 2003; Ding et al, 2003).
 8. km23 is a ubiquitously expressed, cytoplasmic adaptor protein, which when expressed, can stimulate the interaction between Src and Grk2, thereby facilitating the activation of the Ras/Mapk pathways (Fig. 2).

SO WHAT SECTION:

km23 as a "Drugable" Target: Several Different Therapeutic Approaches are Applicable

- km23 appears to function as a tumor suppressor, blocking cancer cell growth under normal conditions. In contrast, km23 alterations in human breast cancer abrogate the tumor suppressive function of km23.
- Several therapeutic approaches have been employed to repair or replace the loss of tumor suppressor protein functions (i.e., gene therapy approaches, blockade of binding proteins, etc); these are also applicable to km23.
- Pharmacological screens are underway to identify novel agents that can restore the normal functions of km23, or replace the altered forms/functions of km23.

REFERENCES:

Campbell KS, Cooper S, Dessing M, Yates S, Buder A. Interaction of p59fyn kinase with the dynein light chain, Tctex-1, and colocalization during cytokinesis. *J. Immunol* 161(4):1728-1737, 1998.

Ding W, Charboneau L, Espina V, Liotta LA, Mulder KM. A TGF β receptor-interacting protein frequently mutated in epithelial ovarian cancer. *Cancer Res.*, in preparation, 2003.

Ding W, Mulder KM. Targeting km23 in human cancers. In *Molecular Targeting and Signaling Transduction: Molecular Therapeutics*. Ed. Kumar, R. Kluwer Academic Publishers, Cancer Treatment and Research Book Series, in preparation, 2004.

Jin Q, Staub CM, Tang Q, Ding W, Gao G, Mulder KM. Role of km23 co-localized and interacted with Smad2 in TGF β -mediated effects. *J. Cell Sci.*, Submitted, 2003.

Karcher RL, Deacon SW, Gelfand VI. Motor-cargo interactions: the key to transport specificity. *Trends Cell Biol* 12(1):21-27, 2002.

Mulder KM. A new target for the development of anti-cancer diagnostics and therapeutics. *Amer. Clin. Lab.*, in preparation, 2003.

Shen X, Li J, Hu PP, Waddell D, Zhang J, Wang XF. The activity of guanine exchange factor NET1 is essential for transforming growth factor-beta-mediated stress fiber formation. *J. Biol. chem.* 276(18):15372-15378, 2001.

Tang Q, Staub C, Gao G, Jin Q, Wang Z, Ding W, Aurigemma R, Mulder KM. A novel TGF β receptor-interacting protein that is also a light chain of the motor protein dynein. *Mol. Biol. Cell* 13:4484-4496, 2002.

Trenkle T, McClelland M, Adlkofer K, Welsh J. Major transcript variants of VAV3, a new member of the VAV family of guanine nucleotide exchange factors. *Gene* 245(1):139-149, 2000.

Vaughan KT, Vallee RB. Cytoplasmic dynein binds dynactin through a direct interaction between the intermediate chains and p150Glued. *J Cell Biol* 131:1507-1516, 1995.

Wan KF, Sami BS, Tate R, Waters C, Pyne NJ. The inhibitory gamma subunit of the type 6 retinal cGMP phosphodiesterase functions to link c-Src and G-protein-coupled receptor kinase 2 in a signaling unit that regulates p42/p44 mitogen-activated protein kinase by epidermal growth factor. *J. Biol. Chem.* 278(20):18658-18663, 2003.

APPENDICES:

Table 1

Table 2

Fig 1

Fig 2

Publication -- Tang Q, Staub CM, Gao G, Jin Q, Wang Z, Ding W, Aurigemma RE, Mulder KM. A novel transforming growth factor- β receptor-interacting protein that is also a light chain of the motor protein dynein. *Molecular Biology of the Cell* 13:4484-4496, 2002.

Publication -- Jin Q, Staub CM, Tang Q, Ding W, Gao G, Mulder KM. Role of km23 co-localized and interacted with Smad2 in TGF β -mediated effects. *J. Cell Sci.*, submitted 2003.

Curriculum Vitae -- Kathleen M. Mulder, Ph.D.

Table 1. Detection of Mutations in Breast Cancer Tissues Using Laser Capture Microdissection & Nested-RT-PCR

Case No.	Age (yrs.)	Histology	Stage/Grade	Mutations
1	48	Infiltrating ductal carcinoma	III/ 3	-
2	48	Infiltrating ductal carcinoma	III/ 3	Missing exon 3

Table 2. km23 alterations in human breast tumors in NCBI database

Human EST- accession No.	Tumor Source	Nucleotide alterations	Amino acid residue alterations	Exon
AI910285	Breast	AAC→ACC	N20T	2nd
		GAC→AAC	D59N	3rd
BI861952	Breast adenocarcinoma cell line	56th deletion	G19E	2nd
		GGA→GAA	87aa	
BG030777	Breast	56th deletion	G19E	2nd
		GGA→GAA	87aa	
H45788	Breast	GTG→GTC	V57V	3rd
		CGT→GGT	R58G	
		237th deletion	87aa	
R50440	Breast	GTG→GTC	V57V	3rd
		CGT→GGT	R58G	
		GAC→GGA	N59G	
BG033914	Mammary adenocarcinoma cell line	56th deletion	G19E	2nd
		GGA→GAA	22aa	
BE077366	Breast	37th, 38th and 47th deletion		2nd
		CAG→CAA	S12P	
		AGC→CCA	20aa	
BF744548	Breast	ACC→ACG	T38T	3rd
		ACC→ATC	T39I	
BF744651	Breast	ACC→ACG	T38T	3rd
		ACC→ATC	T39I	

Fig. 1




Fig. 1: RII does not directly interact with Src. MDCK cells were treated with TGFβ (5 ng/ml) for the indicated times. Lysates were then immunoprecipitated (IP d) with RII Ab (lanes 1 and 2), Src Ab (lanes 4-6), or IgG (lanes 3 and 7, negative control), analyzed by SDS-PAGE, and transferred to PVDF membrane. Top panel: IP RII/ blot Src (lanes 1 and 2) indicates that RII does not interact with Src. However, IP Src/ blot Src indicates Src band at correct position (lanes 4-6). IgG controls had no specific bands (lanes 3 and 7). Bottom panel: IP Src/ blot RII (lanes 4-6) indicates that RII does not interact with Src in the opposite direction. However, IP RII/ blot RII indicates RII band at correct position (lanes 1 and 2). IgG controls had no specific bands (lanes 3 and 7).

Fig. 2




Fig. 2: km23 expression induces an interaction between Src and the adaptor kinase GRK2.

293 cells were transfected with EV of km23-Flag and treated with EGF (50 ng/ml) for the indicated times. Lysates were then immunoprecipitated (IP d) with Src Ab (lanes 1-3), or IgG (lane 4, negative control), analyzed by SDS-PAGE, and transferred to PVDF membrane. Top panel: IP Src/blot GRK2 indicates that treatment with EGF for 5 min stimulates an interaction of GRK2 with Src (lane 2). Transfection of km23 also stimulates the interaction of Src with GRK2 in the absence of EGF stimulation (lane 3). Bottom panel: Equal expression of transfected km23-Flag in the relevant lanes is demonstrated by Western blotting using a Flag Ab (lanes 3 and 4).

A Novel Transforming Growth Factor- β Receptor-interacting Protein That Is Also a Light Chain of the Motor Protein Dynein

Qian Tang,^{*†} Cory M. Staub,^{*†} Guofeng Gao,^{*§} Qunyan Jin,^{*} Zhengke Wang,^{*} Wei Ding,^{*} Rosemarie E. Aurigemma,^{*} and Kathleen M. Mulder^{*||}

^{*}Department of Pharmacology and [§]Intercollege Graduate Program in Genetics, Pennsylvania State University College of Medicine, Hershey, Pennsylvania 17033

Submitted May 1, 2002; Revised August 23, 2002; Accepted August 29, 2002
Monitoring Editor: J. Richard McIntosh

The phosphorylated, activated cytoplasmic domains of the transforming growth factor- β (TGF β) receptors were used as probes to screen an expression library that was prepared from a highly TGF β -responsive intestinal epithelial cell line. One of the TGF β receptor-interacting proteins isolated was identified to be the mammalian homologue of the LC7 family (mLC7) of dynein light chains (DLCs). This 11-kDa cytoplasmic protein interacts with the TGF β receptor complex intracellularly and is phosphorylated on serine residues after ligand-receptor engagement. Forced expression of mLC7-1 induces specific TGF β responses, including an activation of Jun N-terminal kinase (JNK), a phosphorylation of c-Jun, and an inhibition of cell growth. Furthermore, TGF β induces the recruitment of mLC7-1 to the intermediate chain of dynein. A kinase-deficient form of TGF β RII prevents both mLC7-1 phosphorylation and interaction with the dynein intermediate chain (DIC). This is the first demonstration of a link between cytoplasmic dynein and a natural growth inhibitory cytokine. Furthermore, our results suggest that TGF β pathway components may use a motor protein light chain as a receptor for the recruitment and transport of specific cargo along microtubules.

INTRODUCTION

Transforming growth factor- β (TGF β) is the prototype for the TGF β superfamily of highly conserved growth regulatory polypeptides that also includes the activins, inhibins, bone morphogenetic proteins, decapentaplegic (Dpp), nodal, Lefty, and others (Roberts, 1998; Sporn and Vilcek, 2000; Yue and Mulder, 2001). Alterations in the TGF β signaling components and pathways have been implicated in a vast array of human pathologies, including cancer (Massague *et al.*, 2000; Sporn and Vilcek, 2000; Derynck *et al.*, 2001).

TGF β binds to two types of transmembrane serine/threonine kinase receptors (RI and RII) in a heterotetrameric complex, to activate downstream components (Roberts, 1998; Massague *et al.*, 2000; Sporn and Vilcek, 2000; Yue and Mulder, 2001). The Smad family of signaling intermediates plays an important role in mediating TGF β responses (Atti-

sano and Wrana, 2000; ten Dijke *et al.*, 2000; Yue and Mulder, 2001). Moreover, TGF β has been shown to regulate Ras (Mulder and Morris, 1992; Hartsough *et al.*, 1996; Yue *et al.*, 1998) and several components of the mitogen-activated protein kinase (Mapk) pathways (Hartsough and Mulder, 1995; Frey and Mulder, 1997; Mulder, 2000; Sporn and Vilcek, 2000; Yue and Mulder, 2001). In addition to the Ras/Mapk and Smad pathways, several proteins have been identified based upon their interaction with the TGF β receptors (Yue and Mulder, 2001). Furthermore, various Smad-interacting proteins have also been identified, including SARA and Dab2, which interact with both Smads and the TGF β receptors (Tsukazaki *et al.*, 1998; Hocevar *et al.*, 2001; Yue and Mulder, 2001).

Despite advances in our understanding of the mechanisms by which the Smad and Ras/Mapk cascades mediate some TGF β effects, these pathways seem to regulate primarily transcriptional events (Hocevar *et al.*, 1999; Hu *et al.*, 1999; Sporn and Vilcek, 2000; Yue and Mulder, 2000a, 2001). However, TGF β is multifunctional and its biological responses are diverse. Thus, identification of additional TGF β signaling pathways and components will assist in our understanding of the mechanisms by which alterations in these pathways contribute to human disease.

Article published online ahead of print. Mol. Biol. Cell 10.1091/mbc.E02-05-0245. Article and publication date are at www.molbiolcell.org/cgi/doi/10.1091/mbc.E02-05-0245.

[†] These authors contributed equally to this work.

[§] Present address: Lexicon Genetics Inc., 8800 Technology Forest Place, The Woodlands, TX 77381-1160.

^{||} Corresponding author. E-mail address: kmm15@psu.edu.

Dynein is a molecular motor protein that mediates intracellular transport by conveying cargo along polarized microtubules (MTs) toward the minus ends (Hirokawa, 1998). Cytoplasmic dynein superfamily members control various cell functions and are important for establishing epithelial polarity (Tai *et al.*, 2001). Several different subunits of cytoplasmic dynein can bind to a variety of cargoes (Kamal and Goldstein, 2002; Karcher *et al.*, 2002). However, little is known about the regulation of the movement that dynein motors drive. Two dynein intermediate chains (DICs) are known to be important for cargo binding. In addition, most cargoes interact with dynein through dynactin, which binds to DIC (Kamal and Goldstein, 2002; Karcher *et al.*, 2002). Four light intermediate chains (LICs) and several dynein light chains (DLCs) also seem to be involved in imparting proper cargo selection. Finally, a variety of receptor systems and transporters have been shown to bind to molecular motors, either directly through the light chains (LCs), or through motor receptors or adaptor proteins (Klopfenstein *et al.*, 2000; Kamal and Goldstein, 2002; Karcher *et al.*, 2002).

Motor protein binding and transport of cargoes intracellularly sometimes utilizes a set of proteins involved in cell signaling (Bowman *et al.*, 2000; Goldstein, 2001). For example, the Jun N-terminal kinase (JNK)-interacting proteins (JIPs) are thought to serve as scaffolding proteins for the JNK signaling pathway (Davis, 2000). These JIP proteins also bind with high affinity and specificity to the motor protein kinesin (Verhey *et al.*, 2001). It is thought that kinesin carries the JIP scaffolding proteins, preloaded with cytoplasmic and transmembrane signaling molecules. Similarly, dynein-dependent movement of signaling molecules along MTs has been reported. For example, p53 was found to be localized to the MTs and physically associated with tubulin (Giannakakou *et al.*, 2000). The transport of p53 along MTs was dynein dependent, suggesting that the interaction of p53 with dynein facilitated its accumulation in the nucleus after DNA damage (Giannakakou *et al.*, 2000). Furthermore, a receptor-DLC interaction has been reported for the photo-receptor rhodopsin (Tai *et al.*, 1999). The interaction between rhodopsin and Tctex-1 is thought to represent a novel mode of dynein-cargo interaction in which a dynein subunit directly binds to an integral membrane protein cargo molecule that serves as a dynein receptor.

Activation of a motor may occur by posttranslational modifications, local changes in the cellular environment, or chaperone binding (Hollenbeck, 2001). Because growth factors and cytokines are known to regulate such events, the receptors and signaling pathways for these polypeptides are potential mediators of motor protein activation and organelle trafficking, events that ultimately determine the collective spatial organization of the signaling pathways within the cell.

Herein, we describe a mammalian TGF β receptor-interacting protein, termed mLC7-1, which is also a DLC. TGF β stimulates not only the phosphorylation of mLC7-1, but also the recruitment of mLC7-1 to the DIC. Kinase-active TGF β receptors are required for mLC7-1 phosphorylation and interaction with DIC. Recruitment of DLCs to the dynein complex is important not only for specifying the cargo that will bind (Vaughan and Vallee, 1995), but also for the regulation of intracellular transport itself (Karcher *et al.*, 2002). Thus, mLC7-1 seems to function as a motor receptor, linking the dynein motor to specific cargo. We also demonstrate that mLC7-1 can

mediate specific TGF β responses, including JNK activation, c-Jun phosphorylation, and growth inhibition.

MATERIALS AND METHODS

Reagents

The anti-FLAG M2 (F3165) and anti-c-myc (M5546) antibodies and mouse IgG were from Sigma-Aldrich (St. Louis, MO). The anti-DIC monoclonal antibody was from Chemicon (Temecula, CA). The anti-V5 antibody (R960 25) was obtained from Invitrogen (Carlsbad, CA) and the anti-hemagglutinin (HA) antibody (1-583-816) was from Roche Applied Science (Indianapolis, IN). The TGF β RII antibody (SC-220-G or -R), the phospho-c-Jun antibody (KM-1, SC-822), and rabbit IgG were from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A or G agarose were purchased from Invitrogen. 125 I-TGF β (NEX-267), 32 P]orthophosphate (NEX-053), γ - 32 P]ATP (BLU002H), and 3 H]thymidine (NET-027X) were from PerkinElmer Life Sciences (Boston, MA). TGF β_1 was purchased from R & D Systems (Minneapolis, MN).

Cell Culture

COS-1 cells (CRL-1650) and Mv1Lu cells (CCL-64) were obtained from American Type Culture Collection (Manassas, VA) and were grown in DMEM supplemented with 10% fetal bovine serum. 293T cells were obtained from T.-W. Wong (Bristol-Myers Squibb, Princeton, NJ) and were maintained as for COS-1 cells. Madin-Darby canine kidney (MDCK) cells (CCL-34) were grown in minimal essential medium- α , supplemented with 10% fetal bovine serum. Cultures were routinely screened for mycoplasma by using Hoechst staining.

Cloning of TGF β Receptor Targets

Construction of TGF β Receptor Expression Plasmids. The intracellular domains of TGF β RII and RI were polymerase chain reaction (PCR) amplified using the full-length human cDNA's for TGF β RII (Lin *et al.*, 1992) or TGF β RI (Franzen *et al.*, 1993), respectively, as templates. These domains were inserted into the pET15b-mod (containing N-terminal His and FLAG tags) or pET30c (containing N-terminal His and S tags) expression constructs, respectively, and the correct DNA sequences were confirmed.

Expression and Activation of Intracellular Domains. The BLR (DE3) or HMS174 (Novagen) *Escherichia coli* strains were transformed separately with each of the TGF β receptor-containing vectors or the corresponding empty vectors (EVs), followed by selection on kanamycin and ampicillin. Expression was induced with isopropyl β -D-thiogalactoside and verified by Western blotting using tag antibodies that differed for each receptor cytoplasmic domain. Recombinant receptor domains were affinity purified sequentially to isolate heteromeric receptors enriched for the activated complex. In vitro kinase assays (Bassing *et al.*, 1994) were performed to phosphorylate the intracellular domains. Phosphorylation of both RI and RII was confirmed by SDS-PAGE. The higher degree of RI phosphorylation in kinase reactions performed with both receptors, as opposed to only RI, suggested that transphosphorylation of RI by RII had occurred. Supernatants derived from kinase assays with cold ATP were used to approximate the specific activity of 32 P-labeled proteins.

Preparation and Screening of Expression Library from IEC 4-1 Cells. An expression library was prepared from the rat 4-1 IEC line (Mulder *et al.*, 1993) by using the Superscript Choice System for cDNA synthesis (Invitrogen). Double-stranded cDNA ligated to EcoRI adaptors was size selected, and relevant fractions were pooled and ligated into the TriplEx expression vector (CLONTECH, Palo Alto, CA). The ligated DNA was incorporated into phage particles

(Gigapack II gold; Stratagene, La Jolla, CA) and titered by infection of *E. coli* strain XL1-Blue, according to the manufacturer's instructions (CLONTECH). Recombinant phage were screened using a modified CORT protocol (Skolnik *et al.*, 1991). Briefly, the activated intracellular domains of both TGF β receptors (prepared as described above) were incubated with filters, and interactions between phosphorylated receptors and library-expressed proteins were detected by autoradiography. Positive plaques were picked and enriched. Numerous positive clones were identified using this method, of which one will be described in detail herein. A partial cDNA of approx. 463 base pairs was originally isolated and sequenced (kathleen mulder #23 in the series, km23). This partial cDNA was then used to obtain the full-length rat km23 gene, including the 5' and 3' regions. A human placental cDNA library (CLONTECH) was screened to isolate human km23 (hkm23). On comparison of our sequence with human expressed sequence tags in the database, the full-length hkm23 gene was obtained. The nucleotide sequences for human (accession no. AY026513) and rat (AY026512) km23 are available at <http://www.ncbi.nlm.nih.gov:80/entrez>. The protein identifications are AAK18712 and AAK18711, respectively.

Transient Transfections, ¹²⁵I-TGF β Cross-Linking, Immunoprecipitation/blot, Westerns, and In Vivo Phosphorylation Assays

These assays were performed essentially as described previously (Hocevar *et al.*, 1999; Yue *et al.*, 1999a; Yue and Mulder, 2000a). To prepare RI-V5, the Alk-5 cDNA was digested with *NotI* and *XhoI* restriction enzymes, followed by subcloning into pcDNA3.1/V5-His (V-810-20; Invitrogen). To prepare km23-FLAG, the coding region of rat or human km23 was PCR amplified with additional suitable flanking restriction enzyme sites for *BglIII* (5') and *SalI* (3') and inserted into pCMV5-FLAG (Sigma-Aldrich) after digestion with *BglIII* and *SalI* restriction enzymes. 293T, MDCK, COS-1, or Mv1Lu cells were transiently transfected using either LipofectAMINE Plus (catalog no. 10964-013; Invitrogen) or LipofectAMINE 2000 (catalog no. 11668-027; Invitrogen), according to the manufacturer's instructions.

Phosphoamino Acid Analysis

COS-1 cells were transfected and labeled as for in vivo phosphorylation assays. After the cell lysates were normalized for radioactivity, labeled km23/mL7-1 protein was immunoprecipitated with anti-FLAG, separated by SDS-PAGE, transferred, and visualized by autoradiography. The membrane containing ³²P-labeled km23/mL7-1 was excised, and phosphoamino acid analysis was performed as described previously (Boyle *et al.*, 1991).

Stable Transfections

hkm23-FLAG was inserted into a pEGFP-C1 plasmid (CLONTECH) to create an N-terminal GFP tag. The resulting construct or the equivalent EV was transfected into Mv1Lu cells using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's protocol. Twenty-four hours after transfection the cells were split at a ratio of 1:5. After another 24 h, 1000 μ g/ml G418 was added for a selection period of 11 d, at which time surviving colonies were pooled and maintained in the presence of 1000 μ g/ml G418. Expression of km23/mL7-1 was verified by Western blot analysis, and stably transfected pools of km23-FLAG or EV-transfected pools were used for JNK, c-Jun, and growth assays.

JNK In Vitro Kinase Assays

These assays were performed as described previously (Frey and Mulder, 1997; Yue and Mulder, 2000b), except that anti-

JNK (C-17; Santa Cruz Biotechnology) was used for the immunoprecipitations (IPs) and glutathione S-transferase (GST)-c-JUN (1-79) (Santa Cruz Biotechnology) was the substrate.

Growth Assays

The TGF β responsiveness of cells was verified by [³H]thymidine incorporation assays, performed as described previously (Hartsoog and Mulder, 1995). For Figure 5, pools of Mv1Lu cells stably transfected with km23-FLAG or EV were plated at 2×10^3 cells per 96-well dish and were analyzed at several days thereafter using crystal violet (EMScience #1011; Fisher Scientific, Pittsburgh, PA), according to the assay protocol at http://www-ufk.med.uni-rostock.de/lablinks/protocols/e_protocols/cvassay.htm.

GST Pull-Downs

To prepare GST-km23, the coding region of rat or human km23 was PCR amplified with additional suitable flanking restriction enzyme sites for *BamHI* (5') and *XhoI* (3'), and inserted into pGEX-4T-1 (Amersham Biosciences, Piscataway, NJ) after digestion with *BamHI* and *XhoI* restriction enzymes. The bacterially expressed rkm23-GST was isolated according to the manufacturer's instructions (Amersham Biosciences) and used in the GST pull-downs by standard methods (Current Protocols in Molecular Biology). The products were analyzed by SDS-PAGE or immunoblotting/Coomassie staining.

RESULTS

We have developed a novel method for the identification of TGF β receptor-interacting proteins, as depicted in Figure 1A. The phosphorylated, activated cytoplasmic domains of the TGF β receptors were used as probes to screen an expression library that was prepared from a highly TGF β -responsive IEC line (Mulder *et al.*, 1993). The cytoplasmic regions of both receptors were phosphorylated in vitro using a kinase assay before screening, as described in MATERIALS AND METHODS. Figure 1B illustrates the results of an in vitro kinase assay performed using the cytoplasmic regions of the receptors. Lanes 3 and 4 depict the phosphorylated receptor proteins after expression of either RII or RI alone, as indicated. Autophosphorylation of both receptors is clearly visible, as described previously (Lin *et al.*, 1992; Bassing *et al.*, 1994; Chen and Weinberg, 1995). No phosphorylation is visible after expression of only empty vectors (pET 15/30). On expression of both receptor domains (lane 6), there is an increase in the phosphorylation level of both receptors, indicating that trans-phosphorylation was also occurring. These data indicate that the cytoplasmic domains of RI and RII can interact and become catalytically activated in vitro. These phosphorylated receptor domains were used to screen the expression library as illustrated in Figure 1A.

Several positive clones were isolated as described in MATERIALS AND METHODS. Among the clones isolated, km23 was pursued initially because early database searches identified the *Drosophila* bithoraxoid (bxd) region of the bithorax complex (BX-C) as being most closely related. The BX-C is a cluster of homeotic genes that transcribe positional information into segmental identity for specific parasegments (Morata and Kerridge, 1981; Martin *et al.*, 1995). bxd is a 40-kb region of BX-C, immediately upstream from the Ultrabithorax (Ubx) unit, and capable of exerting *cis*-regulatory control over expression of this unit (Lipshitz *et al.*, 1987). It had already been shown that the TGF β superfamily member Dpp stimulated transcription of Ubx and that the Ubx protein was necessary




Figure 1. Identification of a novel TGF β receptor-interacting protein. (A) Method for identifying TGF β receptor-interacting proteins. The cytoplasmic domains of both receptors were expressed, sequentially isolated, kinase-activated in vitro, and used as probes to screen an expression library. (B) In vitro kinase activation of the cytoplasmic regions of TGF β RI and RII result in both auto- and trans-phosphorylation. Bacterially expressed TGF β receptor proteins were precipitated with Ni²⁺-NTA agarose beads before performing an in vitro kinase assay. Bacterial lysates were prepared after expression of either EVs (pET15, pET30, and pET15/pET30), the intracellular domains of RII or RI alone (pET15-His-RII-FLAG and pET30-His-RI-S), or together (pET15-His-RII-FLAG/pET30-His-RI-S).

but not sufficient for full activation of dpp expression (Mathies *et al.*, 1994; Sun *et al.*, 1995; Eresh *et al.*, 1997). Thus, it was conceivable that a homologue of the regulatory region of Ubx might be important in TGF β signaling. In addition, the TGF β superfamily of secreted polypeptides is known to convey critical signals during the control of development in various contexts, and BX-C is also important in development.

Several other clones were obtained in our screen, including a previously recognized TGF β RI-interacting protein, the alpha subunit of farnesyl protein transferase (Kawabata *et al.*, 1995; Ventura *et al.*, 1996). The other clones identified in our screen will be the subjects of future investigations. We would not have expected to identify Smads in our screen, because we used

catalytically active TGF β receptors as the probes. It has been proposed that activation of RSmads by RI releases them from the complex, to mediate downstream signaling. For example, Macias-Silva *et al.* (1996) have demonstrated that the interaction between the TGF β receptor complex and Smad2 was increased when RI was made inactive by mutation of the kinase domain. Furthermore, Lo *et al.* (1998) have shown that removal of the C-terminal domain of Smad2 increased its interaction with RI, suggesting that docking was inhibited when the C-tail was phosphorylated. Therefore, in our screen, the in vitro kinase assay performed on the receptors before library screening would be expected to prevent binding of Smads to the receptor complex.

The novel TGF β signaling intermediate we identified, initially termed km23, is a 96-amino acid protein encoded by a 291-base pair open reading frame. It is a ubiquitously expressed, cytoplasmic protein with a predicted molecular mass of 10.667 kDa and a calculated molecular mass of 11 kDa on Western blots. The rat and human km23 amino acid sequences differ by only three amino acids and are 98% similar. Additional alignments of km23 with sequences in the National Center for Biotechnology Information database indicated that km23 is the mammalian homologue of the *Drosophila* protein roadblock (robl), which belongs to the LC7 family of *Chlamydomonas* DLCs (chlLC7) (Bowman *et al.*, 1999). robl is a light chain of the motor protein dynein that interacts with the DIC. It is involved in mitosis and axonal transport. Mutants lacking this gene display defects in intracellular transport, and an accumulation of cargoes, as well as an increase in the mitotic index.

Table 1 lists the percentage of homologies, identities, and similarities of some of the DLCs of the km23/robl/LC7 family. Differences in the number of amino acids are also shown. As indicated, there is a second mammalian member of the LC7 family in the National Center for Biotechnology Information database. This form of mLC7 (designated mLC7-2 in Table 1; AA446298) displays 70% homology with the km23/mLC7-1 form we have identified. In contrast, a total of five LC7/robl-like genes have been identified in *Drosophila*, yet *Caenorhabditis elegans* seems to have only a single km23/robl-like gene (National Center for Biotechnology Information database T24H10.6; Bowman *et al.*, 1999). There does not seem to be a family member in *Saccharomyces cerevisiae*. There are also other DLC families that bind to DIC, including Tctex-1/LC14, Tctex-2/LC2, LC6, and LC8/PIN (Bowman *et al.*, 1999; King, 2000; Makokha *et al.*, 2002). Of these other DLCs that bind to the DIC, Tctex-1 and LC8 have been shown to function as motor receptors to link cargo to the motor machinery (Almenar-Queralt and Goldstein, 2001). Although Tctex-1 and LC8 share limited sequence identity, both bind a number of unrelated cargo in a similar manner (Mok *et al.*, 2001; Makokha *et al.*, 2002). Similarly, these DLCs are only 8 and 14% identical to mLC7-1, respectively. It is conceivable that mLC7-1 also mediates motor complex assembly and connection to the transported cellular cargo.

Because we had identified mLC7-1 by its ability to interact with the cytoplasmic regions of the TGF β receptors, it was of interest to verify whether mLC7-1 was present in association with the TGF β receptors intracellularly. Accordingly, affinity cross-linking experiments were performed using ¹²⁵I-TGF β (Yue *et al.*, 1999a). Figure 2A indicates that both RI and

Table 1. Comparison of km23/mLC7-1 to some other family members

Homologue	Species	% Homology	% Identity	% Similarity	Amino acids
mLC7-2	<i>Homo sapiens</i>	70	77	91	96
robl	<i>Drosophila melanogaster</i>	67	71	81	97
ch/LC7	<i>Chlamydomonas</i>	59	55	74	105
bxid-like	<i>C. elegans</i>	56	47	76	95
bxid	<i>D. melanogaster</i>	42	23	51	101

RII are present in km23/mLC7-1 immunocomplexes (lane 5) from cell lysates of 293T cells, which had been transiently transfected with both TGF β receptors and km23-FLAG. The positions of RI and RII were confirmed by analysis of total cell lysates (lane 2). Unlabeled TGF β completely competed for binding to both receptors as shown in lane 6 (Figure 2A). Furthermore, no receptors were detectable in FLAG IPs after

expression of both receptors without km23/mLC7-1 (our unpublished data). The control blots in the lower panels demonstrate that the appropriate constructs were expressed to similar levels. Thus, these results suggest that mLC7-1 is associated with the activated receptor complex.

To determine whether the interaction between the receptors and mLC7-1 occurred rapidly after ligand stimulation,




Figure 2. Verification of TGF β receptor interaction with mLC7-1. (A) RI and RII TGF β receptors are present in mLC7-1 immunocomplexes. 293T cells were transiently transfected with km23-FLAG, RI-myc, RII-HA, and/or EVs, and affinity labeling was performed. After the 4-h 125 I-TGF β labeling period (4°C), the cross-linking agent disuccinimidyl suberate was added for an additional 15 min. Top, total cell lysates (lanes 1 and 2) or lysates immunoprecipitated with an anti-FLAG M2 antibody (lanes 3–6) or with IgG (lane 7, control) were visualized by SDS-PAGE and autoradiography. No bands were visible in FLAG IPs after transfection of only RI and RII (our unpublished data). Bottom, Western blots for FLAG, myc, and HA demonstrate expression of the relevant constructs (lanes 2 and 4–6 for km23/mLC7-1; lanes 2, 5, and 6 for RI and RII). (B) Interaction between mLC7-1 and the TGF β receptors occurs within 5 min of TGF β addition. 293T cells were transiently transfected with km23-FLAG, RI-V5, RII-HA, and/or EVs, followed by IP/blot analyses with FLAG as the IP antibody and an RII polyclonal antibody as the blotting antibody (top). Cells were incubated in serum-free medium for 60 min before addition of TGF β for the indicated times. Bottom, controls for expression and loading of km23/mLC7-1 (FLAG blot), RI (V5 blot), and RII (RII blot). (C) TGF β induces a rapid association of mLC7-1 with endoge-

nous TGF β receptors in MDCK cells. EV or km23-FLAG constructs were expressed in MDCK cells, and TGF β treatments and IP/blot analyses were performed as for Figure 2B. (D) mLC7-1 interacts with RII via IP/blot analyses in 293T cells. Cells were transiently transfected with km23-FLAG and RII-HA as indicated. Top, cell lysates were immunoprecipitated with anti-FLAG or HA and blotted with an HA antibody. The presence of RII in lanes 3 and 4, but not in lanes 1 and 2, demonstrates an interaction between km23-FLAG and RII-HA. Bottom, lysates were immunoprecipitated with anti-HA and blotted with anti-FLAG. The presence of km23/mLC7-1 in only lane 3 indicates that an interaction between km23-FLAG and RII-HA is detectable in this direction as well. Results are representative of two experiments for each.

we performed IP/blot analyses in the presence and absence of TGF β . Coexpression of both TGF β receptors is known to result in heteromeric complex formation and receptor activation in the absence of ligand (Ventura *et al.*, 1994), as shown in Figure 2B (lane 4). However, Figure 2B demonstrates not only that km23/mLC7-1 interacts with RII, but also that TGF β induces this interaction within 5 min of TGF β addition (lanes 4–6, top). The appearance of the RII band with slightly slower mobility (lanes 5 and 6) suggests that TGF β also induced the interaction of km23/mLC7-1 with a differentially phosphorylated/modified form of RII. No specific band was apparent after expression of only km23/mLC7-1 or the receptors alone (lanes 2 and 3, top). We were unable to assess whether RI was also present in the complex using this assay, due to the interference of the IgG bands at the RI position on such blots. However, because an RII antibody was used as the blotting antibody in these experiments, our data indicate that mLC7-1 does associate with RII.

To ensure that the interaction was not the result of overexpression of the TGF β receptors, we performed similar IP/blot analyses in MDCK cells expressing endogenous TGF β receptors. These cells are TGF β responsive as revealed by a 70% inhibition of cell growth within 24 h of 10 ng/ml TGF β addition (our unpublished data). As seen in Figure 2C, TGF β induced a rapid interaction between km23/mLC7-1 and endogenous TGF β receptors. The kinetics were similar to those observed for the 293T cells. Thus, TGF β induces the interaction of mLC7-1 with the TGF β receptors in two different cell types, and without overexpression of the receptors.

The results in Figure 2, A–C, are consistent with mLC7-1 interacting with both receptors in the complex simultaneously or with RII alone, due to the fact that RII interacts with and controls ligand binding to the complex (Wrana *et al.*, 1992). To determine whether both receptors were required for mLC7-1 interaction with the receptor complex, we performed IP/blot analyses after expression of only RII in 293T cells. Figure 2D depicts the interaction of km23/mLC7-1 with RII, either using FLAG as the IP antibody, and the HA antibody as the blotting antibody (top), or by performing the analyses in the reverse direction (bottom). As indicated by the results in either direction, it seems that km23/mLC7-1 can interact with RII alone. In contrast, upon expression of RI alone, no detectable interaction of RI with mLC7-1 was observed (our unpublished data). However, because 293T cells do express a low level of endogenous RI receptors, overexpression of RII could cause an interaction of RII with the endogenous RI receptors. It is possible, then, that some RI is still present in the receptor complex in Figure 2D. Thus, mLC7-1 may interact with the receptor complex through the RII receptor, and RI may not be a direct binding partner. In contrast, expression of RII alone may be sufficient for TGF β regulation of mLC7-1.


TGF β receptors have serine/threonine kinase activity, which can mediate the phosphorylation of intracellular proteins as one mechanism for initiating TGF β signaling events and responses. Thus, if mLC7-1 is a component of a TGF β signaling cascade, it is conceivable that the TGF β receptors could phosphorylate mLC7-1 as a mechanism for activation. To determine whether mLC7-1 was phosphorylated by the TGF β receptors, we performed *in vivo* phosphorylation assays (Yue and Mulder, 1999a,b) after transient expression of km23/mLC7-1 and both receptors, each being detectable by distinct tag antibodies,

as indicated in Figure 3A. From the results in the top panel, it is clear that the TGF β receptor complex resulted in phosphorylation of km23/mLC7-1 (lane 5). Expression of km23/mLC7-1 alone did not result in a band at the km23/mLC7-1 position (lane 2), indicating that mLC7-1 is not constitutively phosphorylated when expressed in these cells. The IgG and FLAG binding peptide control lanes (7 and 8) indicate that the band noted is specific for km23/mLC7-1.

After complex formation, the TGF β receptors are known to become phosphorylated on specific serine and threonine residues (Souhelnytskyi *et al.*, 1996). Moreover, TGF β receptor activation affects the phosphorylation of specific serine residues in RSmads, which are required for TGF β signaling (Souhelnytskyi *et al.*, 1997). Thus, if mLC7-1 is a substrate for the TGF β receptor kinase activity, phosphorylation of mLC7-1 on serine residues might be expected. To examine whether this was the case, we performed phosphoamino acid analysis of phosphorylated mLC7-1 obtained after coexpression of km23/mLC7-1 and both TGF β receptors in COS-1 cells, similar to the analyses for Figure 3A in 293T cells. Figure 3B indicates that km23/mLC7-1 is phosphorylated primarily on serine residues in response to TGF β receptor activation. These findings are consistent with mLC7-1 functioning as a substrate for the kinase activity of the TGF β receptors. Conversely, mLC7-1 does not seem to stimulate the kinase activity of the receptors (our unpublished data).

Based upon the current model for TGF β receptor activation, RII mediates the phosphorylation of RI and the activation of downstream TGF β components and responses (Roberts, 1998; Massague *et al.*, 2000; Sporn and Vilcek, 2000; Yue and Mulder, 2001). Accordingly, if TGF β activation of the receptor complex is required for phosphorylation of mLC7-1, expression of a kinase-deficient version of RII (KN-RII) would be expected to block mLC7-1 phosphorylation. Figure 3C (top) depicts the results of *in vivo* phosphorylation of km23/mLC7-1 after coexpression of either wild-type RII (lanes 2 and 3) or KN-RII (lane 4) with wild-type RI. As shown previously, km23/mLC7-1 alone was not constitutively phosphorylated (lane 1), and expression of both TGF β receptors with km23/mLC7-1 resulted in km23/mLC7-1 phosphorylation (lane 2). Figure 3C indicates, furthermore, that TGF β treatment for 15 min enhanced km23/mLC7-1 phosphorylation (lane 3). This phosphorylation of km23/mLC7-1 was completely blocked upon expression of the KN-RII (lane 4), thereby demonstrating that the kinase activity of RII is required for mLC7-1 phosphorylation.

To determine whether RI was also required for mLC7-1 phosphorylation, we performed similar *in vivo* phosphorylation experiments using various kinase-active and kinase-deficient versions of RI. Figure 3D confirmed that expression of both receptors with km23/mLC7-1 induced km23/mLC7-1 phosphorylation (lane 4) and that KN-RII blocked this phosphorylation (lane 7). However, in addition, this figure indicates that km23/mLC7-1 is still phosphorylated after coexpression of RII with KN-RI (lane 9). Only limited phosphorylation of Smad2 has been reported to occur under such conditions (Macias-Silva *et al.*, 1996). Because the KN-RI would be expected to abrogate any residual activity from endogenous RI receptors present in COS-1 cells, these data suggest that the RI kinase is not required for phosphorylation of mLC7-1, although it is present in mLC7-1 immunocomplexes with RII by affinity-labeling experiments (Figure 2A). Lane 11 in Figure 3D dem-



onstrates no detectable phosphorylation of km23/mLC7-1 after expression of a constitutively active RI mutant (T204D). However, when wild-type RII was coexpressed with this mutant, km23/mLC7-1 phosphorylation was observed (lane 13), presumably due to the kinase activity of RII. Collectively, the data suggest that although both receptors may be present in a complex with mLC7-1, the RII kinase is required for mLC7-1 phosphorylation. The data do not rule out the possibility that another kinase is also present in the complex.

The method of isolation of mLC7-1, as well as the results in Figures 2 and 3, suggest that mLC7-1 may function as a signaling intermediate for TGFβ. Thus, it was of interest to examine whether mLC7-1 could mediate any of the known TGFβ signaling events. We have previously shown that TGFβ rapidly activates the JNK family of Mapks (Frey and Mulder, 1997). Furthermore, JNK activation by TGFβ is required for such TGFβ responses as production of TGFβ, and induction of fibronectin expression (Hocavar *et al.*, 1999; Yue and Mulder, 2000a). JNK activation by TGFβ may also play a role in TGFβ-mediated growth inhibition, either through the amplification of TGFβ production, via cross talk with the Smads, and/or by regulation of cell cycle inhibitors (Derynck *et al.*, 2001; Yue and Mulder, 2001).

To determine the effect of forced expression of wild-type mLC7-1 on JNK activation, we stably expressed a FLAG-tagged version of km23/mLC7-1 in mink lung epithelial cells (Figure 4A, third panel) and performed *in vitro* kinase assays to determine the ability of JNK to phosphorylate GST-c-Jun in

Figure 3. A functional RII TGFβ receptor is required for mLC7-1 phosphorylation. (A) mLC7-1 is phosphorylated upon activation of TGFβ receptors. 293T cells were transiently transfected with RI-V5, RII-HA, and either EV or km23-FLAG. Forty-eight hours after transfection, cells were labeled for 3 h with [³²P], lysed, and immunoprecipitated with an anti-FLAG antibody. Top, *in vivo* phosphorylation of km23/mLC7-1 was visualized by SDS-PAGE and autoradiography. A blocking peptide (b.p.) for the FLAG antibody was added in lane 8. Bottom, expression of transfected km23-FLAG was confirmed by immunoblot analysis. Results are representative of three experiments. (B) activation of the TGFβ receptors results in phosphorylation of mLC7-1 primarily on serine residues. km23/mLC7-1 was phosphorylated *in vivo* as for A, and phosphoamino acid analysis was performed. ³²P-labeled km23/mLC7-1 was excised from the polyvinylidene difluoride membrane and subjected to acid hydrolysis (6 M HCl, 1 h, 110°C). Phosphoserine (pS), phosphothreonine (pT), and phosphotyrosine (pY) were separated in two dimensions by using Hunter Thin Layer Peptide Mapping Electrophoresis System (CBS Scientific, Del Mar, CA), together with phosphoamino acid standards. Labeled and standard phosphoamino acids were visualized by ninhydrin spray (0.25% in acetone). ³²P-labeled phosphorylated amino acids were visualized by autoradiography. (C) TGFβ cannot phosphorylate mLC7-1 when a kinase-deficient RII is expressed with RI. COS-1 cells were transiently transfected as in A, except that the KNRII was coexpressed with wild-type RI in lane 4. Cells were incubated in serum-free, phosphate-free medium for 30 min and TGFβ was added during the last 15 min of the labeling period (lanes 3 and 4). Lysates were analyzed as for A. Top, *in vivo* phosphorylation of km23/mLC7-1. Bottom, expression of transfected km23/mLC7-1, RI, and RII was confirmed by Western blot analysis with FLAG, V5, and a polyclonal RII antibody, respectively, as indicated. Results are representative of two experiments. (D) Kinase activity of RI does not seem to be required for phosphorylation of mLC7-1. *In vivo* phosphorylation assay and transfection of COS-1 cells was performed as for Figure 3C, except that no TGFβ was added and different receptor mutants were evaluated as indicated. Results are representative of two experiments.

the absence and presence of TGF β . As shown in Figure 4A, in the EV-expressing cells, TGF β began activating JNK within 10 min of TGF β addition; JNK activity increased further by 30 min posttreatment (top, left). These kinetics are similar to those obtained for other cell types (Frey and Mulder, 1997). In contrast, when km23/mLC7-1 was stably expressed in these cells, JNK was superactivated in the absence of TGF β (top, right). JNK activity was ~15 times greater in the km23/mLC7-1-expressing cells than in the EV-expressing cells during the 2- to 10-min period after TGF β addition. By 30 min post-TGF β treatment, JNK activation levels were more similar between the km23/mLC7-1- and EV-expressing cells. These findings suggest that mLC7-1 may function as a signaling intermediate for the activation of JNK by TGF β .

Previous results have indicated that c-Jun, a downstream effector of JNK, can be phosphorylated by TGF β (Huang *et al.*, 2000). To determine whether this downstream effector of JNK could also be phosphorylated by stable expression of mLC7-1, we performed immunoblot analysis at various times after TGF β treatment using a phospho-c-Jun-specific antibody. This antibody is specific for c-Jun phosphorylated at serine-63, and does not cross-react with unphosphorylated c-Jun or with the phosphorylated forms of Jun B or Jun D. These studies were performed in the same Mv1Lu cells stably expressing km23/mLC7-1 that were used for Figure 4A. The results in Figure 4B demonstrate that forced expression of km23/mLC7-1 induced the phosphorylation of c-Jun in the absence of TGF β (comparing left and right, top). As for JNK activity, c-Jun phosphorylation was superactivated in the absence of TGF β . Figure 4B, bottom, indicates that c-Jun phosphorylation levels were approximately 10 times greater in the km23/mLC7-1-expressing cells than in the EV-expressing cells. Collectively, the results in Figure 4 suggest that mLC7-1's cellular effects on JNK and c-Jun activation are downstream of TGF β receptor activation.

In addition, our findings in Figure 4 suggest that overexpression of mLC7-1 may result in the constitutive activation of specific TGF β signaling components and pathways. These intermediates may, in turn, be involved in mediating specific TGF β responses in the absence of ligand activation of receptors. Accordingly, because one of TGF β 's most prominent biological effects is growth inhibition of epithelial cells, we examined whether overexpression of mLC7-1 in the Mv1Lu-transfected pools could result in growth inhibition in the absence of TGF β . The results in Figure 5 indicate that, relative to EV-transfected pools, the km23/mLC7-1-expressing cells were growth inhibited by ~50%. These data support the contention that overexpression of mLC7-1 may mediate some TGF β responses in a constitutive manner. Alternatively, with regard to the growth inhibitory effect observed, the overexpression of mLC7-1 may have disrupted the interaction of cytoplasmic dynein with the kinetochore, thereby reducing growth. Similar results have been reported upon overexpression of dynactin, a dynactin subunit that can disrupt the dynein/dynactin interaction (Echeverri *et al.*, 1996).

As mentioned above, mLC7-1 is the mammalian homologue of the *chILC7* and *Drosophila* *robl* proteins, which are DLCs (Bowman *et al.*, 1999). Accordingly, it was of interest to determine whether mLC7-1 could interact with the DIC as *chILC7*/robl does. As shown in Figure 6A, we performed GST pull-down assays after expressing and purifying GST-km23. An anti-DIC antibody was used as the blotting antibody to detect the presence of dynein in the GST-km23 complexes. This anti-




Figure 4. mLC7-1 expression can induce JNK and result in phosphorylation of the downstream target c-Jun. (A) Stable expression of mLC7-1 results in activation of JNK in the absence of TGF β . Top, Mv1Lu cell pools, stably transfected with either empty vector (lanes 1–4) or km23-FLAG (lanes 5–8), were incubated in serum-free medium for 30 min before addition of 10 ng/ml TGF β for the indicated times. Cell lysates were immunoprecipitated with anti-JNK (C-17; Santa Cruz Biotechnology) and subjected to *in vitro* kinase assays using GST-c-Jun (1–79) as the substrate. The phosphorylated proteins were resolved by SDS-PAGE and visualized by autoradiography. Normal rabbit IgG was used as the negative control. Middle, equal JNK and km23/mLC7-1 expression was confirmed by Western blotting. Bottom, plot of densitometric scan of results in top. (B) Stable expression of mLC7-1 results in phosphorylation of c-Jun in the absence of TGF β . Top, cells were treated with TGF β and lysates were obtained as for Figure 4A, except that they were analyzed by Western blot analysis with a phospho-c-Jun antibody (KM-1 and SC-822). Middle, Western blot demonstrating equal km23/mLC7-1 expression in the pools stably expressing km23/mLC7-1, but not in the EV-transfected pools. Bottom, plot of densitometric scan of results in top. Results are representative of two experiments for each.




Figure 5. Stable expression of mLC7-1 results in growth inhibition in the absence of TGF β . Mv1Lu cell pools stably expressing km23/mLC7-1 or EV were plated and analyzed for cell number at several days thereafter as indicated, by using the crystal violet assay described in MATERIALS AND METHODS. The percentage of inhibition of growth is indicated in parentheses on top of the relevant bars.

body detects a protein of ~74 kDa. In Figure 6A, it is clear that dynein is visible in GST-km23 immunoprecipitates (lane 2), but not in immunoprecipitates from GST alone (lane 1). The interaction between the Smad binding domain (SBD) of SARA and Smad2-FLAG (Tsukazaki *et al.*, 1998) is shown as a positive control for comparison (lane 4). The results clearly demonstrate that mLC7-1 is a dynein-associated protein.

The finding that mLC7-1 associates with and is phosphorylated by activated TGF β receptors, and that it can activate JNK and c-Jun and inhibit cell growth, suggests that mLC7-1 may function in a TGF β signaling pathway. Furthermore, because it is thought that DLCs may be important for specifying the nature of the cargo that will be carried by the motor (Klopfenstein *et al.*, 2000; Kamal and Goldstein, 2002), it is likely that extracellular factors (such as growth factors and cytokines) might be able to select the particular DLCs that are recruited to the motor in specific cellular contexts. Accordingly, it was of interest to determine whether TGF β could mediate the recruitment of mLC7-1 to the DIC. For these studies, we performed IP/blot analyses by using anti-DIC as the IP antibody and anti-FLAG as the blotting antibody. Figure 6B, top, demonstrates that km23/mLC7-1 does interact with cytoplasmic DIC by IP/blot analyses. In addition, as shown in lanes 3–5 and 8–10 of this figure, 10 ng/ml TGF β induced a rapid recruitment of km23/mLC7-1 to the DIC. Although a basal level of interaction between km23/mLC7-1 and DIC was detectable in some cases (lane 2), a threefold increase in this association was visible within 15 min of TGF β addition to the TGF β -responsive MDCK cells. This increase in the interaction between km23/mLC7-1 and DIC began as early as 2 min after TGF β addition (top right) and seemed to remain relatively constant for at least 60 min (lanes 4 and 5, top). The bottom panels demonstrate roughly equal expression and loading. Thus, TGF β rapidly induced the recruitment of the mLC7-1 to the DIC.

The results in Figure 6B indicate that TGF β can stimulate the recruitment of mLC7-1 to the DIC, suggesting a connection between TGF β signaling and DLC recruitment. To provide definitive evidence that TGF β receptor activation is required for the mLC7-1–DIC interaction, we examined the interaction between mLC7-1 and DIC in the absence and presence of a

kinase-deficient form of TGF β RII. This receptor mutant can function in a dominant negative manner to block the kinase activity of endogenous RII when overexpressed in cells (Wieser *et al.*, 1993). Furthermore, we have shown in Figure 3D that expression of KN RII with wild-type RI does not permit mLC7-1 phosphorylation. Figure 6C indicates that the TGF β -induced interaction between km23/mLC7-1 and DIC (lanes 3–5) was blocked when KN RII was expressed (lanes 7–10). No specific band was detectable in EV and IgG control lanes. Expression of km23/mLC7-1 and KN RII in the relevant lanes was also confirmed (middle and bottom panels). Thus, mLC7-1 phosphorylation by kinase-active TGF β receptors is necessary for the recruitment of mLC7-1 to the DIC.


DISCUSSION

Our results provide a novel method for the identification of TGF β signaling components, based upon their ability to bind to the phosphorylated intracellular domains of the TGF β receptors. Furthermore, we have verified the success of this method with the isolation of a unique TGF β receptor-interacting protein, termed mLC7-1. The mLC7-1 interaction with the TGF β receptors was confirmed by 125 I-TGF β affinity labeling and by IP/blot analysis. Furthermore, TGF β induced the interaction of mLC7-1 with endogenous TGF β receptors within 5 min of ligand addition in MDCK cells, and a similar kinetic profile was observed in at least one other cell type. Finally, mLC7-1 was able to transduce specific TGF β signaling events, including an activation of JNK, a phosphorylation of c-Jun, and an inhibition of cell growth.

We have also shown that TGF β receptor activation results in the phosphorylation of mLC7-1 primarily on serine residues, consistent with the kinase specificity for the receptors. For example, the RSmads are activated by serine phosphorylation at a C-terminal SSxS motif (Souchevnytskyi *et al.*, 1997). Although this could suggest that mLC7-1 is a direct substrate of the TGF β receptor kinase activity, it is also possible that another kinase is associated with the mLC7-1/TGF β receptor complex. There are consensus phosphorylation sites for protein kinase C and casein kinase II within the mLC7-1 coding region. Perhaps, these or other serine kinases are the immediate activators of mLC7-1. However, it is clear that TGF β does stimulate the interaction of mLC7-1 with the receptors, and that TGF β receptor activation leads to mLC7-1 phosphorylation and recruitment of mLC7-1 to DIC.

Our results indicate, furthermore, that the kinase activity of the RII receptor is required for mLC7-1 phosphorylation and interaction with DIC, because a kinase-deficient version of RII blocked TGF β induction of both events. TGF β RI did not seem to be required for mLC7-1 phosphorylation, although RI was present in mLC7-1 immunoprecipitates in affinity-labeling experiments. Several pieces of evidence support the conclusion that RII is the activating receptor for mLC7-1. First, coexpression of RII with a kinase-deficient version of RI induced mLC7-1 phosphorylation to an extent equivalent to that which occurred by expression of RII alone. Second, expression of both TGF β receptors resulted in no additional increase in km23/mLC7-1 phosphorylation compared with expression of only RII. Finally, constitutively active RI alone did not result in phosphorylation of mLC7-1, as it does for the RSmads. Similarly, previous studies have described TGF β signaling molecules that were regulated specifically by the RII receptors. For

Figure 6. Interaction between the mLC7-1 and the DIC is regulated by TGF β and requires RII kinase activity. (A) mLC7-1 interacts with DIC via GST pull-down assays. Top, MDCK cell lysates were incubated with Sepharose-bound bacterially expressed GST alone, GST-km23, or GST-SBD (positive control). GST-bound proteins were analyzed by SDS-PAGE (10%) and were immunoblotted with an anti-DIC antibody. Proteins were detected by enhanced chemiluminescence. Dynein interacts with GST-km23 (lane 2), but not with GST alone (lane 1). The interaction between FLAG-tagged Smad2 and GST-SBD (Tsukazaki *et al.*, 1998) was confirmed as a positive control (lane 4). Bottom, Coomassie staining of gel in top panel, demonstrating the presence of GST and GST fusion proteins in the relevant lanes. The sizes are as expected for the different fusion proteins (approx. 37 kDa for GST-km23; approx. 35 kDa for GST-SBD) or GST alone (approx. 27 kDa). (B) TGF β stimulates the recruitment of the mLC7-1 to the DIC within 2 min of TGF β treatment. MDCK cells were transiently transfected with either empty vector or km23-FLAG. Thirty-six hours after transfection, cells were incubated in serum-free medium for 60 min before addition of 10 ng/ml TGF β for the indicated times. Cell lysates were subjected to IP by using a monoclonal anti-DIC antibody, followed by immunoblot analysis with an anti-FLAG antibody (top). Western blot analysis with anti-FLAG (middle) or anti-DIC (bottom) demonstrates equal protein expression and loading. The right side shows the results at earlier time points. Results are representative of three experiments. (C) Phosphorylation of mLC7-1 is required for recruitment of mLC7-1 to the DIC. Cell treatments and IP/blot analyses were performed in MDCK cells as for B, except that cells were transfected with km23-FLAG in the absence (left, top) or presence (right, top) of KN RII. Western blot controls for expression of km23/mLC7-1 and KN RII are shown in the middle and bottom panels, respectively.



example, the Daxx adaptor protein has been proposed to mediate TGF β -induced apoptosis through its interaction with RII (Perlman *et al.*, 2001).

Based upon the report describing the cloning of the *Drosophila* robl protein and the *chILC7* (Bowman *et al.*, 1999), kn23/mLC7-1 is the mammalian homologue of the DLC/LC7/robl. We have shown that TGF β leads to the recruitment of mLC7-1 to the DIC in a rapid, TGF β -inducible manner. This interaction, however, occurred within a slightly different time frame than the interaction of mLC7-1 with the TGF β receptors. This finding suggests that the receptors themselves may not be the cargo that dynein will transport via mLC7-1. That is, the mLC7-1-receptor interaction peaks at 5 min, and seems to begin declining by 15 min after TGF β addition (Figure 2, B and C), consistent with the receptors being released once mLC7-1 has been phosphorylated. In contrast, it is clear from Figure 6, B and C, that the interaction between mLC7-1 and DIC begins as early as 2 min after TGF β addition, yet mLC7-1 is still bound to DIC at 60 min after TGF β addition. Previous studies have indicated that the transport of p53 along MTs was dynein dependent, suggesting that the interaction of p53 with dynein facilitated its accumulation in the nucleus after DNA damage (Giannakakou *et al.*, 2000). Similarly, subsequent to receptor activation, TGF β signaling components may be transported along the MTs through the interaction of mLC7-1 with DIC.

Although evidence indicates that Smads 2/3/4 may be distributed along the MT network, the MTs seemed to sequester the Smads from the receptor before cellular stimulation by TGF β (Dong *et al.*, 2000). Perhaps this occurs because a motor protein light chain such as mLC7-1 is in an inactive, unphosphorylated state until TGF β receptor activation occurs. Phosphorylation of the DLC may affect a conformational change in this protein, followed by its recruitment to a motor complex for transport of TGF β signaling components (i.e., Smads and JNKs) along the MTs.

A link between TGF β receptor signaling and the minus-end MT motor protein dynein has not been demonstrated previously. However, a receptor-DLC interaction has been reported for the photoreceptor rhodopsin (Tai *et al.*, 1999). In addition, the Trk neurotrophin receptors have been shown to associate with the DLC Tctex-1, suggesting that transport of neurotrophins during vesicular trafficking may occur through this direct interaction between the Trk receptor and the dynein motor machinery (Yano *et al.*, 2001). It has been shown that nerve growth factor remains bound to TrkA after endocytosis, thereby allowing the receptor to continue to activate signaling proteins (Grimes *et al.*, 1996). In the case of TGF β , however, the receptor location for either initiation or transmission of TGF β signaling activities has not been clearly defined. It has been shown that heteromeric TGF β receptors are internalized and down-regulated after TGF β activation via a clathrin-dependent mechanism (Anders *et al.*, 1997; Doré *et al.*, 1998) and that the kinase activity of RII is required for these processes to occur optimally (Anders *et al.*, 1998). A more recent report has indicated that Smad phosphorylation does not occur until the GTPase dynamin 2ab excises the budded vesicle from the plasma membrane to form an endocytic vesicle (Penheiter *et al.*, 2002). This report also demonstrated that the formation and activation of the receptor complex was not sufficient for Smad signaling, and that an activity or activities downstream of dynamin 2ab function was/were required. It is possible that mLC7-1 recruitment to the DIC, and dynein motoring of TGF β

signaling components along the MTs, represent at least some of these activities.

Because vesicles derived from a donor compartment fuse with specific acceptor membranes to directionally transfer cargo molecules during trafficking (Gonzalez and Scheller, 1999), it is likely that distinct events occur in different cell compartments during TGF β signaling. Thus, the fate of the TGF β -receptor complex and specific signaling complexes may differ. With regard to the *Drosophila* TGF β superfamily member Dpp, the rates of endocytic trafficking and degradation determine Dpp signaling range (Entchev *et al.*, 2000). A similar situation may exist for TGF β in mammalian cells. However, further investigation will be required for a complete understanding of how TGF β receptor endocytosis, intracellular trafficking, and cell signaling events are integrated.

Collectively, our data are consistent with a role for mLC7-1 in both TGF β signaling and dynein-mediated transport along MTs. It is likely that the binding of mLC7-1 to the DIC after TGF β receptor activation is important for specifying the nature of the cargo that will be transported along the MTs. Any disruption in mLC7-1 could prevent or alter movement of specific cargo along MTs. In this way, alterations in mLC7-1 might result in a mislocalization of these proteins, with a disruption of TGF β growth inhibitory signals. Along these lines, protein traffic direction is required for the maintenance of cell polarity, which, if lost, can result in tumor formation (Peifer, 2000; Bilder *et al.*, 2000). Accordingly, sequence alterations at specific regions of mLC7-1 in human tumors might play a role in tumor development or progression. Future studies will address this possibility.

ACKNOWLEDGMENTS

We thank L. Liotta (National Cancer Institute, Bethesda, MD) and T.W. Wong (Bristol-Myers Squibb, Princeton, NJ) for helpful discussions. We appreciate the assistance of S. R. Hann and M.A. Gregory (Vanderbilt University, Nashville, TN) with the phosphoamino acid analysis procedure. We also thank J. Massague (Memorial Sloan-Kettering Cancer Center, New York, NY) for KNRI-HA and KNRH-HA; J. Wrana (Samuel Lunenfeld Res. Institute, Toronto, Canada) for pCMV5-HA-TGF β RII, Smad2-FLAG, and GST-SBD; R. Derynck (University of California, San Francisco) for RI-myc; K. Miyazono (University of Tokyo, Tokyo, Japan) for the Alk-5 RI cDNA; Q. Chen (Pennsylvania State University College of Medicine, Hershey, PA) for the pcDNA3.1/V5-His vector; H. Lodish (Massachusetts Institute of Technology, Cambridge, MA) for the RII cDNA; H. Moses (Vanderbilt) for the T204D RI; and T.W. Wong for pFLAG-CMV5 and for preparing the RI-pFLAG-CMV5 expression construct. This work was supported by National Institutes of Health grants CA-51452, CA-54816, CA-68444, CA-90765, and CA-92889, and Dept of Defense award DAMD17-0110592 (to K.M.M.).

REFERENCES

- Almenar-Queralt, A., and Goldstein, L.S.B. (2001). Linkers, packages and pathways: new concepts in axonal transport. *Curr. Opin. Neurobiol.* 11, 550-557.
- Anders, R.A., Arline, S.L., Doré, J.J.E., and Leof, E.B. (1997). Distinct endocytic responses of heteromeric and homomeric transforming growth factor receptors. *Mol. Biol. Cell* 8, 2133-2143.
- Anders, R.A., Doré, Jr., J.J.E., Arline, S.L., Garamszegi, N., and Leof, E.B. (1998). Differential requirement for type I and type II transforming growth factor receptor kinase activity in ligand-mediated receptor endocytosis. *J. Biol. Chem.* 273, 23118-23125.

- Attisano, L., and Wrana, J.L. (2000). Smads as transcriptional co-modulators. *Curr. Opin. Cell Biol.* 12, 235–243.
- Bassing, C.H., Yingling, J.M., Howe, D.J., Wang, T., He, W.W., Gustafson, M.L., Shah, P., Donahoe, P.K., and Wang, X.F. (1994). A transforming growth factor β type I receptor that signals to activate gene expression. *Science* 263, 87–89.
- Bilder, D., Li, M., and Perrimon, N. (2000). Cooperative regulation of cell polarity and growth by *Drosophila* tumor suppressors. *Science* 289, 113–116.
- Bowman, A.B., Kamal, A., Ritchings, B.W., Philip, A.V., McGrail, M., Gindhart, J.G., and Goldstein, L.S.B. (2000). Kinesin dependent axonal transports is mediated by the Sunday driver (SYD) protein. *Cell* 103, 583–594.
- Bowman, B., Patel-King, R.S., Benashski, S.E., McCaffery, J.M., Goldstein, L.S., and King, S.M. (1999). *Drosophila* roadblock and Chlamydomonas LC7: a conserved family of dynein-associated proteins involved in axonal transport, flagellar motility, and mitosis. *J. Cell Biol.* 146, 165–180.
- Boyle, W.J., van der Geer, P., and Hunter, T. (1991). Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer cellulose plates. *Method Enzymol.* 201, 110–149.
- Chen, F., and Weinberg, R.A. (1995). Biochemical evidence for the autophosphorylation and transphosphorylation of transforming growth factor β receptor kinases. *Proc. Natl. Acad. Sci. USA* 92, 1565–1569.
- Davis, R.J. (2000). Signal transduction by the JNK kinase group of MAP kinases. *Cell* 103, 239–252.
- Derynck, R., Akhurst, R.J., and Balmain, A. (2001). TGF- β signaling in tumor suppression and cancer progression. *Nat. Genet.* 29, 117–129.
- Dong, C., Li, Z., Alvarez, Jr., R., Feng, X.H., and Goldschmidt-Clermont, P.J. (2000). Microtubule binding to Smads may regulate TGF β activity. *Mol. Cell.* 5, 27–34.
- Doré, Jr., J.J.E., Edens, M., Garamszegi, N., and Leof, E.B. (1998). Heteromeric and homomeric transforming growth factor-receptors show distinct signaling and endocytic responses in epithelial cells. *J. Biol. Chem.* 273, 31770–31777.
- Echeverri, C.J., Paschal, B.M., Vaughan, K.T., and Vallee, R.B. (1996). Molecular characterization of the 50-kD subunit of dynactin reveals function for the complex in chromosome alignment and spindle organization during mitosis. *J. Cell Biol.* 132, 617–633.
- Entchev, E.V., Schwabedissen, A., and Gonzalez-Gaitan, M. (2000). Gradient formation of the TGF- β homolog Dpp. *Cell* 103, 981–991.
- Eresh, S., Riese, J., Jackson, D.B., Bohmann, D., and Bienz, M. (1997). A CREB-binding site as a target for *decapentaplegic* signaling during *Drosophila* endoderm induction. *EMBO J.* 16, 2014–2022.
- Franzen, P., ten Dijke, P., Ichijo, H., Yamashita, H., Schulz, P., Heldin, C.H., and Miyazono, K. (1993). Cloning of a TGF- β type I receptor that forms a heteromeric complex with the TGF- β type II receptor. *Cell* 75, 681–692.
- Frey, R.S., and Mulder, K.M. (1997). Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. *Cancer Res.* 57, 628–633.
- Giannakakou, P., Sackett, D.L., Ward, Y., Webster, K.R., Blagosklonny, M.V., and Fojo, T. (2000). p53 is associated with cellular microtubules, and is transported to the nucleus by dynein. *Nat. Cell Biol.* 2, 709–717.
- Goldstein, L.S. (2001). Transduction. When worlds collide—trafficking in JNK. *Science* 291, 2102–2103.
- Gonzalez, Jr., L., and Scheller, R.H. (1999). Regulation of membrane trafficking: structural insights from a Rab/effector complex. *Cell* 96, 755–758.
- Grimes, M.L., Zhou, J., Beattie, E.C., Yuen, E.C., Hall, D.E., Valletta, J.S., Topp, K.S., LaVail, J.H., Bunnett, N.W., and Mobley, W.C. (1996). Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling endosomes. *J. Neurosci.* 16, 7950–7964.
- Hartsough, M.T., Frey, R.S., Zipfel, P.A., Buard, A., Cook, S.J., McCormick, F., and Mulder, K.M. (1996). Altered transforming growth factor- β signaling in epithelial cells when ras activation is blocked. *J. Biol. Chem.* 271, 22368–22375.
- Hartsough, M.E., and Mulder, K.M. (1995). Transforming growth factor β activation of p44mapk in proliferating cultures of epithelial cells. *J. Biol. Chem.* 270, 7117–7124.
- Hirokawa, N. (1998). Kinesin and dynein superfamily proteins and the mechanism of organelle transport. *Science* 279, 519–526.
- Hocevar, B.A., Brown, T.L., and Howe, P.H. (1999). TGF- β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. *EMBO J.* 18, 1345–1356.
- Hocevar, B.A., Smine, A., Xu, X.-X., and Howe, P.H. (2001). The adaptor molecule disabled-2 links the transforming growth factor β receptors to the Smad pathway. *EMBO J.* 20, 2789–2801.
- Hollenbeck, P.J. (2001). Kinesin delivers: identifying receptors for motor proteins. *J. Cell Biol.* 152, F25–F27.
- Hu, P.P., Shen, X., Huang, D., Liu, Y., Counter, C., and Wang, X.F. (1999). The MEK pathway is required for stimulation of p21(WAF1/CIP1) by transforming growth factor- β . *J. Biol. Chem.* 274, 35381–35387.
- Huang, Y., Hutter, D., Liu, Y., Wang, X., Sheikh, M.S., Chan, A.M., and Holbrook, N.J. (2000). Transforming growth factor- β suppresses serum deprivation-induced death of A549 cells through differential effects on c-Jun and JNK activities. *J. Biol. Chem.* 275, 18234–18242.
- Kamal, A., and Goldstein, L.S. (2002). Principles of cargo attachment to cytoplasmic motor proteins. *Curr. Opin. Cell Biol.* 14, 63–68.
- Karcher, R.L., Deacon, S.W., and Gelfand, V.I. (2002). Motor-cargo interactions: the key to transport specificity. *Trends Cell Biol.* 12, 21–27.
- Kawabata, M., Imamura, T., Miyazono, K., Engel, M.E., and Moses, H.L. (1995). Interaction of the transforming growth factor- β type I receptor with farnesyl-protein transferase- α . *J. Biol. Chem.* 270, 29628–29631.
- King, S.M. (2000). The dynein microtubule motor. *Biochim. Biophys. Acta* 1496, 60–75.
- Klopfenstein, D.R., Vale, R.D., and Rogers, S.L. (2000). Motor protein receptors: moonlighting on other jobs. *Cell* 103, 537–540.
- Lin, H.Y., Wang, X.-F., Ng-Eaton, E., Weinberg, R.A., and Lodish, H.F. (1992). Expression cloning of the TGF- β type II receptor, a functional transmembrane serine/threonine kinase. *Cell* 68, 775–785.
- Lipshitz, H.D., Peattie, D.A., and Hogness, D.S. (1987). Novel transcripts from the Ultrabithorax domain of the bithorax complex. *Genes Dev.* 1, 307–322.
- Lo, R.S., Chen, Y.-G., Shi, Y., Pavletich, N.P., and Massague, J. (1998). The L3 loop: a structural motif determining specific interactions between SMAD proteins and TGF β receptors. *EMBO J.* 17, 996–1005.
- Macias-Silva, M., Abdollah, S., Hoodless, P.A., Pirone, R., Attisano, L., and Wrana, J.L. (1996). MADR2 is a substrate of the TGF β receptor and its phosphorylation is required for nuclear accumulation and signaling. *Cell* 87, 1215–1224.
- Makokha, M., Hare, M., Li, M., Hays, T., and Barbar, E. (2002). Interactions of cytoplasmic dynein light chains Tctex-1 and LC8 with the intermediate chain IC74. *Biochem. J.* 41, 4302–4311.
- Martin, C.H., Mayeda, C.A., Davis, C.A., Ericsson, C.L., Knafels, J.D., Mathog, D.R., Celniker, S.E., Lewis, E.B., and Palazzolo, M.J. (1995). Complete sequence of the bithorax complex of *Drosophila*. *Proc. Natl. Acad. Sci. USA* 92, 8398–8402.

- Massagué, J., Blain, S.W., and Lo, R.S. (2000). TGF- β signaling in growth control, cancer, and heritable disorders. *Cell* 103, 295–309.
- Mathies, L.D., Kerridge, S., and Scott, M.P. (1994). Role of the teashirt gene in *Drosophila* midgut morphogenesis: secreted proteins mediate the action of homeotic genes. *Development* 120, 2799–2809.
- Mok, Y.-K., Lo, K.W.-H., and Zhang, M. (2001). Structure of Tctex-1, and its interaction with cytoplasmic dynein intermediate chain. *J. Biol. Chem.* 276, 14067–14074.
- Morata, G., and Kerridge, S. (1981). Sequential functions of the bithorax complex of *Drosophila*. *Nature* 290, 778–781.
- Mulder, K.M. (2000). Role of Ras and Mapks in TGF β signaling. *Cytokine Growth Factor Rev.* 11, 23–35.
- Mulder, K.M., and Morris, S.L. (1992). Activation of p21ras by transforming growth factor β in epithelial cells. *J. Biol. Chem.* 267, 5029–5031.
- Mulder, K.M., Segarini, P.R., Morris, S.L., Ziman, J.M., and Choi, H.G. (1993). Role of receptor complexes in resistance or sensitivity to growth inhibition by TGF- β in intestinal epithelial cell clones. *J. Cell Physiol.* 154, 162–174.
- Peifer, M. (2000). Cell biology. Travel bulletin – traffic jams cause tumors. *Science* 289, 67–69.
- Penheiter, S.G., Mitchell, H., Garamszegi, N., Edens, M., Doré, Jr., J.J.E., and Leof, E.B. (2002). Internalization-dependent and -independent requirements for transforming growth factor β receptor signaling via the Smad pathway. *Mol. Cell. Biol.* 22, 4750–4759.
- Perlman, R., Schieman, W.P., Brooks, M.W., Lodish, H.F., and Weinberg, R.A. (2001). TGF- β -induced apoptosis is mediated by the adaptor protein Daxx that facilitates JNK activation. *Nat. Cell Biol.* 3, 708–714.
- Roberts, A.B. (1998). Molecular and cell biology of TGF- β . *Miner. Electrolyte Metab.* 24, 111–119.
- Skolnik, E.Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., and Schlessinger, J. (1991). Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. *Cell* 65, 83–90.
- Souchelnytskyi, S., Tamaki, K., Engstrom, U., Wernstedt, C., ten Dijke, P., and Heldin, C.H. (1997). Phosphorylation of Ser465 and Ser467 in the C terminus of Smad2 mediates interaction with Smad4 and is required for transforming growth factor- β signaling. *J. Biol. Chem.* 272, 28107–28115.
- Souchelnytskyi, S., ten Dijke, P., Miyazono, K., and Heldin, C.H. (1996). Phosphorylation of Ser165 in TGF- β type I receptor modulates TGF- β -induced cellular responses. *EMBO J.* 15, 6231–6240.
- Sporn, M.B., and Vilcek J.T. (eds) (2000). Cytokine and Growth Factor Reviews – TGF β Special Issue 11, 1–168.
- Sun, B., Hursh, D.A., Jackson, D., and Beachy, P.A. (1995). Ultrabithorax protein is necessary but not sufficient for full activation of decapentaplegic expression in the visceral mesoderm. *EMBO J.* 14, 520–535.
- Tai, A.W., Chuang, J.-Z., Bode, C., Wolfrum, U., and Sung, C.-H. (1999). Rhodopsin's carboxy-terminal cytoplasmic tail acts as a membrane receptor for cytoplasmic dynein by binding to the dynein light chain Tctex-1. *Cell* 97, 877–87.
- Tai, A.W., Chuang, J.-Z., and Sung, C.-H. (2001). Cytoplasmic dynein regulation by subunit heterogeneity and its role in apical transport. *J. Cell Biol.* 153, 1499–1509.
- ten Dijke, P., Miyazono, K., and Heldin, C.-H. (2000). Signaling inputs converge on nuclear effectors in TGF- β signaling. *Trends Biochem. Sci.* 25, 64–70.
- Tsukazaki, T., Chiang, T.A., Davison, A.F., Attisano, L., and Wrana, J.L. (1998). SARA, a FYVE domain protein that recruits Smad2 to the TGF- β receptor. *Cell* 95, 779–791.
- Vaughan, K.T., and Vallee, R.B. (1995). Cytoplasmic dynein binds dynactin through a direct interaction between the intermediate chains and p150^{glued}. *J. Cell Biol.* 131, 1507–1516.
- Ventura, F., Doody, J., Liu, F., Wrana, J.L., and Massague, J. (1994). Reconstitution and transphosphorylation of TGF- β receptor complexes. *EMBO J.* 13, 5581–5589.
- Ventura, F., Liu, F., Doody, J., and Massague, J. (1996). Interaction of transforming growth factor- β receptor I with farnesyl-protein transferase- α in yeast and mammalian cells. *J. Biol. Chem.* 271, 13931–13934.
- Verhey, K.J., Meyer, D., Deehan, R., Blenis, J., Schnapp, B.J., Rapoport, T.A., and Margolis, B. (2001). Cargo of kinesin identified as JIP scaffolding proteins and associated signaling molecules. *J. Cell Biol.* 152, 959–970.
- Wieser, R., Attisano, L., Wrana, J.L., and Massague, J. (1993). Signaling activity of transforming growth factor β type II receptors lacking specific domains in the cytoplasmic region. *Mol. Cell. Biol.* 13, 7239–7247.
- Wrana, J.L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.F., and Massague, J. (1992). TGF β signals through a heteromeric protein kinase receptor complex. *Cell* 71, 1003–14.
- Yano, H., Lee, F.S., Kong, H., Chuang, J.-Z., Arevalo, J.C., Perez, P., Sung, C.-H., and Chao, M.V. (2001). Association of Trk neurotrophin receptors with components of the cytoplasmic dynein motor. *J. Neurosci.* 21, RC125, 1–7.
- Yue, J., Buard, A., and Mulder, K.M. (1998). Blockade of TGF β_3 up-regulation of p27Kip1 and p21Cip1 by expression of RasN17 in epithelial cells. *Oncogene* 17, 47–55.
- Yue, J., Frey, R.S., Hartsough, M.T., Frielle, T., and Mulder, K.M. (1999a). Cloning and expression of a rat Smad1: regulation by TGF- β and modulation by the Ras/MEK pathway. *J. Cell Physiol.* 178, 387–396.
- Yue, J., Frey, R.S., and Mulder, K.M. (1999b). Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF- β . *Oncogene* 18, 2033–2037.
- Yue, J., and Mulder, K.M. (2000a). Requirement of Ras/MAPK pathway activation by transforming growth factor β for transforming growth factor β -1 production in a Smad-dependent pathway. *J. Biol. Chem.* 275, 30765–30773.
- Yue, J., and Mulder, K.M. (2000b). Activation of the mitogen-activated protein kinase pathways by transforming growth factor- β . In: *Transforming Growth Factor β Protocols*, vol. 142, Louisville, KY: Humana Press, 125–131.
- Yue, J., and Mulder, K.M. (2001). Transforming growth factor- β signal transduction in epithelial cells. *Pharmacol. Ther.* 91, 1–34.

Role of km23 co-localized and interacted with Smad2 in TGF β -mediated effects

**Qunyan Jin*, Cory M. Staub*, Qian Tang[†], Wei Ding*, Guofeng Gao*[§]
and Kathleen M. Mulder*^{§†}**

***Department of Pharmacology, Pennsylvania State University
College of Medicine, 500 University Dr., Hershey, PA 17033**

**[†]Current address: Lexicon Genetics Inc., 8800 Technology Forest Place, The
Woodlands, TX 77381-1160**

[§]Intercollege Graduate Program in Genetics

[†]To whom correspondence should be addressed:

Department of Pharmacology—MC H078

Penn State College of Medicine

500 University Drive, Hershey, PA 17033

Telephone 717-531-6789; FAX 717-531-5013

E-mail kmm15@psu.edu

Running title: Novel TGF β -receptor interacting protein

Key words: TGF β , dynein, motor protein, signal transduction, growth regulation, siRNA

SUMMARY

Transforming growth factor β (TGF β) is a potent growth inhibitor for epithelial cells, often displaying tumor-suppressor activity. We have identified km23 as a novel TGF β receptor-interacting protein. Here we show that km23 is ubiquitously expressed in human tissues and that cell-type specific differences in endogenous km23 protein expression exist. In addition, we demonstrate that the phosphorylation of km23 was TGF β -dependent. Further, the kinase activity of both TGF β receptors appeared to play a role in the TGF β -mediated phosphorylation of km23. Subcellular fractionation analyses revealed that km23 is a cytoplasmic protein. In addition, immunofluorescence analyses indicate that km23 is colocalized with the TGF β signaling component Smad2, either in the absence of TGF β treatment, or during early time periods after its addition. km23 also interacted with Smad2 in glutathione-S-transferase (GST) pull-down and immunoprecipitation (IP)/blot assays. Blockade of km23 using small interfering RNA (siRNA) significantly decreased the ability of TGF β to inhibit thymidine incorporation. Our findings suggest that km23 is necessary, but not sufficient, for TGF β -mediated inhibition of DNA synthesis.

INTRODUCTION

TGF β is growth inhibitory for normal cells of endothelial, hematopoietic, neuronal, and epithelial origin (Piez and Sporn, 1993; Akhurst and Derynck, 2001; Yue and Mulder, 2001). However, cancers are often refractory to this growth inhibitory effect, due to genetic loss of TGF β receptors or, more commonly, perturbation of TGF β signaling pathways (Akhurst and Derynck, 2001; Yue and Mulder, 2001). In fact, most of the components of TGF β signal transduction pathways have been shown to be involved in a tumor suppressor pathway (Sporn and Vilcek, 2000; Akhurst and Derynck, 2001; Attisano and Wrana, 2002).

Resistance to growth inhibition by TGF β due to a lack of TGF β receptor expression has been reported for a variety of different human cancer cell lines, including gastric and colon cancer cells (Hartsough and Mulder, 1997; Kim et al., 2000; Massague et al., 2000). In a number of colon cancers, resistance to TGF β -mediated growth inhibition is associated with mutations in either RII or in the signal transducers Smad4 and Smad2 (Hartsough and Mulder, 1997; Fink et al., 2001). Defects in TGF β receptors and in Smad2 have been reported in ovarian cancer (Wang et al., 2000). Mutations in RI have been reported in head and neck cancer metastases, metastatic breast cancer, and ovarian cancer (Chen et al., 1998; Chen et al., 2001a; b). In addition, alterations in Smad4 have been reported for pancreatic carcinomas and colon carcinomas (Massague et al., 2000; Derynck et al., 2001; Yue and Mulder, 2001). However, such alterations only account for TGF β resistance in a small percentage of

tumors (Akhurst and Derynck, 2001; Yue and Mulder, 2001). Thus, alterations in novel TGF β signaling components are likely to be found.

In addition to cancer, aberrant TGF β signaling results in developmental disorders, including hereditary chondrodysplasia and persistent mullerian duct syndrome, as well as others (Wall and Hogan, 1994; Massague et al., 2000; Yue and Mulder, 2001; Attisano and Wrana, 2002). TGF β superfamily members play a role in almost every cellular process, including early embryonic development, cell growth, differentiation, cell motility, and apoptosis (Hartsough and Mulder, 1997; Massague, 1998; Roberts, 1998). Since TGF β is an important factor in the development of such a large number of human diseases, any component that can be shown to play a role in TGF β -mediated cellular events is of interest to explore.

TGF β initiates its signals by producing an active tetrameric receptor complex consisting of RI and RII serine/threonine kinase receptors. After TGF β binds to RII, it transphosphorylates, and thereby activates RI. The active receptor complex then propagates signals to downstream cellular components and regulatory proteins (Feng and Derynck, 1997; Attisano and Wrana, 1998; Massague et al., 2000; Miyazono, 2000; Sporn and Vilcek, 2000; ten Dijke et al., 2000). Two primary signaling cascades downstream of the TGF β receptors have been elucidated: the Smads and the Ras/mitogen-activated protein kinase (MAPK) pathways (Yue and Mulder, 2001). In addition, several TGF β receptor-interacting factors (Yue and Mulder, 2001) and Smad-interacting factors (ten Dijke et al., 2000) have been reported. Further, NF- κ B, SnoN/Ski oncoproteins, and others have been shown to act as negative regulators of

TGF β signaling, often by regulating the Smad proteins (Massague et al., 2000; Derynck et al., 2001; Yue and Mulder, 2001). However, the mechanisms by which TGF β elicits its numerous biological effects have not nearly been defined.

We have previously identified a novel TGF β receptor-interacting protein that is also a light chain of the motor protein dynein (Tang et al., 2002). This TGF β signaling intermediate, termed km23, interacts with the receptor complex through TGF β RII and it is phosphorylated after TGF β receptor activation. Here we show that km23 is a ubiquitously expressed cytoplasmic protein. Further, TGF β mediated a rapid increase in km23 phosphorylation, and the kinase activity of both receptors appeared to play some role in this phosphorylation event. Immunofluorescence studies revealed that km23 is colocalized with Smad2 before Smad2 is translocated to the nucleus. In addition, km23 interacted with Smad2 in GST pull-down and IP/blot assays. Blockade of km23 using siRNA decreased the ability of TGF β to inhibit DNA synthesis in Madin Darby canine kidney (MDCK) epithelial cells. Our findings suggest that km23 plays a role in mediating the inhibitory effect of TGF β , and that Smad2 is likely involved in this pathway.

MATERIALS AND METHODS

Reagents--The anti-Flag M2 (F3165) antibody (Ab) and mouse IgG were from Sigma-Aldrich (St. Louis, MO). The anti-dynein intermediate chain (DIC) monoclonal Ab (MAB1618) and anti-Lamin A/C Ab (MAB3211) were from Chemicon (Temecula, CA). The anti-hemagglutinin (HA) Ab (1-583-816) was from Roche Applied Science (Indianapolis, IN). The TGF β RII Ab (SC-220-R), K-Ras Ab (SC-30), Sp1 Ab (SC-59) and rabbit IgG were from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). The Smad2 Ab (51-1300) was from Zymed Laboratories (South San Francisco, CA). Protein A or G agarose were purchased from Invitrogen (Carlsbad, CA). 32 P-orthophosphate (NEX-053), γ - 32 P-ATP (BLU002H), and [3 H]thymidine (NET-027X) were from PerkinElmer Life Sciences (Boston, MA). TGF β_1 was purchased from R & D Systems (Minneapolis, MN). The human tissue mRNA blot was purchased from BD Biosciences Clontech (Palo Alto, CA). Alexa 594 goat anti-rabbit IgG and Alexa 488 goat anti-mouse IgG (H+L) were purchase from Molecular probes (Eugene, OR). Anti-Smad2/3 mAb was (610843) from BD Biosciences transduction laboratories (Palo Alto, CA). Anti-Myc (06-549) was from Upstate Biotechnology (Waltham, MA).

Antibody production--The rabbit km23 anti-serum used for Western blotting studies was prepared against the following sequence: GIPIKSTMDNPTTTQYA (corresponding to amino acids 27-43) of hkm23 by either Strategic BioSolutions (Newark, DE) or Covance Reseach Products, Inc. (Denver, PA). Preimmune serum was also provided by each company. The rabbit km23 anti-serum used for the immunofluorescence

studies was prepared against the following sequence: MAEVEETLKRIQS

(corresponding to amino acids 1-13 of hkm23) by Strategic BioSolutions.

Cell culture--Mv1Lu (CCL-64), 293 (CRL-1573), and COS-1 (CRL-1650) cells were purchased from American Type Culture Collection (Manassas, VA) and were grown in DMEM supplemented with 10% FBS. MDCK cells (CCL-34) and HepG2 cells (HB-8065) were also obtained from ATCC and were grown in MEM- α supplemented with 10% FBS. 293T cells were obtained from T-W. Wong (Bristol-Myers Squibb, Princeton, NJ) and were maintained as for 293 cells. OVCA 433 cells were obtained from R.C. Bast Jr. (M.D. Anderson Cancer Center, Houston, TX) and were maintained in MEM supplemented with 10% FBS. FET cells were maintained as described previously (Zipfel et al., 1993). Cultures were routinely screened for mycoplasma using Hoechst 33258 staining.

Transient transfections, IP/blot, Westerns, and In vivo phosphorylation assays were performed essentially as described previously (Hocevar et al., 1999; Yue et al., 1999a; b; Yue and Mulder, 2000; Tang et al; 2002).

siRNA expression--siRNA was purchased from Dharmacon Research (Lafayette, CO) and interference was performed according to the manufacturer's recommendations. The double-stranded siRNA corresponded to nucleotides 77-97 of the hkm23 coding region (5'-AAGGCATTCCCATCAAGAGCA-3'). siRNA was transfected using Oligofectamine (12252-011; Invitrogen).

Fluorescence microscopy--Cells were fixed with 4% paraformaldehyde in phosphate-buffered saline for 20 minutes at room temperature, and permeabilized with 0.5% Triton X-100 in phosphate-buffered saline for 5 minutes. Subsequently, these cells

were incubated successively with km23 rabbit anti-serum (1:200) or 5 µg/ml anti-Smad2/3 mAb for one hour. The bound primary antibodies were visualized with 5 µg/ml Alexa 594 goat anti-rabbit IgG or Alexa 488 goat anti-mouse IgG, respectively. Finally, immunofluorescence images were captured using a Nikon Diaphot microscope with a Retiga 1300 CCD camera (BioVision Technologies, Inc., Exton, PA) running IPLab v3.6.3 software (Scanalytics, Inc., Fairfax, VA).

Cellular fractionation--The NE-PER Nuclear and Cytoplasmic Extraction Reagent kit (78833; Pierce, Rockford, IL) was used to fractionate Mv1Lu cells according to the manufacturer's protocol.

[³H]thymidine incorporation assays were performed as described (Hartsough and Mulder, 1995).

Statistical analyses--A Student's t-test was used to determine the level of statistical significance of the decrease in [³H]thymidine incorporation by TGFβ between siRNA-treated and mock-treated MDCK cells.

GST pull-downs were performed as described (Tang et al., 2002).

RESULTS

km23 is a novel TGF β receptor-interacting protein that is also a light chain of the motor protein dynein (Tang et al., 2002). As indicated in Fig. 1, hkm23 is very similar to the *Danio Rerio* (Zebrafish) ZFIN (80% identity or 93% similarity), *Drosophila robl* (68% identity or 82% similarity), and *Chlamydomonas* LC7 (55% identity or 81% similarity) sequences. In addition, a counterpart of km23 in *Caenorhabditis elegans* (T24H10.6) displays 56% homology to hkm23, and the predicted protein would be 76% similar. In contrast, hkm23 displays 71% similarity to *Spermatozopsis* B15 (Dole et al., 2000), 54% similarity to *Drosophila* bithoraxoid (bxd) and only 33% homology (predicted protein would be 32% similar) to *Leishmania* LMAJFV1 (Akopyants et al., 2001). The single-celled flagellar parasite *Leishmania* is an animal-like, Protozoan form of Protista, the Kingdom that also includes plant-like forms of green algae, such as *Chlamydomonas* and *Spermatozopsis*. Thus, km23 displays a considerable degree of conservation across different Kingdoms and Phyla.

There also appears to be another mammalian km23 form, designated km23-2 in Table 1. Table 1 lists the % homologies, identities, and similarities of hkm23 compared with the rat and mouse sequences for the two forms. As indicated, rkm23-1 (96% identity or 98% similarity) and mkm23-1 (95% identity or 98% similarity) are highly conserved when compared with hkm23. In addition, hkm23-2 displays 70% homology and 91% similarity with hkm23-1. Similarly, the rat and mouse forms of km23-2 display 71% homology and 91% similarity with hkm23-1. We have also sequenced the cadnine km23-1 from a.a ? to ?, and this region, it displays /% identity

Thus, the mammalian forms of both km23-1 and km23-2 have very similar sequence , although they may be ? distinct.

In order to determine the tissue distribution of hkm23, we performed Northern blot analysis using a human tissue blot obtained from BD Biosciences Clontech. The coding region of hkm23-1 was used as the probe (Fig. 2, top). The blots were stripped and reprobed with β -actin cDNA as a control for equal loading of RNA (Fig. 2, middle). Both blots were then scanned by densitometry and the km23 values were corrected for differences in RNA loading using the β -actin levels (Fig. 2, bottom). As indicated in Fig. 2, km23 was expressed at a high level in brain, kidney, and placenta. Intermediate levels of expression were observed in the heart, skeletal muscle, and liver. Low levels were detectable in the colon, spleen, small intestine, and lung. In longer exposures, barely detectable levels were observed in the thymus and in peripheral blood leukocytes. The calculated size of the hkm23-1 mRNA from the blot was approximately 0.7 kb.

The cellular effects of TGF β are dependent upon cell type, stage of differentiation, growth conditions, concentration of ligands, and the presence of other growth factors (Roberts and Sporn, 1990; Yue and Mulder, 2001). Since km23 was identified as a TGF β receptor-interacting protein, it was of interest to determine whether TGF β could modulate the expression of the endogenous km23 protein. In order to perform these studies, we developed polyclonal rabbit km23 anti-serum against amino acids 27-43 of hkm23 and performed Western blot analysis in MDCK epithelial cells to determine whether the km23 anti-serum was specific. As indicated

in Fig. 3A (left panel), the rabbit km23 anti-serum specifically recognized a single band of 11 kDa by Western blot analysis (left panel, lanes 1-4). This band was not present after blotting with preimmune serum (right panel, lane 2). The results of Fig. 3 clearly indicate that TGF β does not induce the expression of endogenous km23 (left panel, lanes 1-4).

In order to determine whether cell-type specific differences in km23 protein expression existed, we examined the relative expression levels of endogenous km23 in various mammalian cell types. Due to the high level of similarity (98%) among the mammalian km23-1 forms from amino acids 27-43, the polyclonal km23 anti-serum could detect endogenous km23 levels equally well in the different species. As shown in Fig. 3B, km23 is highly expressed in HepG2 human hepatoma cells (lane 4, top panel) and in MDCK cells (lane 6, top panel), while Mv1Lu mink lung epithelial cells (lane 5, top panel) displayed reduced expression levels. We also found that the expression level of km23 in the TGF β -resistant, human ovarian cancer cell line OVCA 433 (lane 3, top panel) was lower than that in either the MDCK or HepG2 cells. km23 was expressed at intermediate levels in 293 human embryonic kidney cells (lane 1, top panel) and in TGF β -responsive FET human colon cancer cells (lane 2, top panel). Equal loading was confirmed by blotting with a DIC Ab (bottom panel), since we have previously determined that DIC levels are relatively constant among such cell lines. Thus, cell-type specific differences in km23 protein expression do exist.

In order to examine the subcellular localization of km23, we performed Western blot analysis after subcellular fractionation of cells incubated in the presence or absence of TGF β . As indicated in Fig. 4, when km23 was expressed in the absence of

TGF β (lanes 1-6, left panel), both endogenous and expressed km23 were easily detectable in the cytoplasmic fraction (lane 3, top panel). In contrast, as expected, endogenous Lamins A and C were not detectable in the cytoplasmic fraction (lanes 1-3, bottom panel). Further, both endogenous and expressed km23 were absent in the nuclear fraction (lanes 4-6, top panel), whereas Lamins A and C were easily detectable in this compartment (lanes 4-6, bottom panel) (Georgatos et al., 1994). The results indicate that km23 is a cytoplasmic protein. A similar result was observed after the cells were exposed to TGF β (lanes 7-12, right panel), indicating that TGF β treatment does not affect a nuclear translocation of km23. As expected, no change in the localization of Lamins A and C was detected after TGF β treatment.

The serine/threonine kinase activity of the TGF β receptors mediates phosphorylation of downstream molecules to affect TGF β responses. We have previously shown that km23 was phosphorylated by the TGF β receptor complex in human embryonic kidney 293T cells (Tang et al, 2002). However, we did not examine the ligand-dependent role of TGF β in km23 phosphorylation in those cells. Here, we performed *in vivo* phosphorylation assays (Yue et al., 1999a; b) after transient expression of km23-flag, RI-HA, and RII-HA in the absence and presence of TGF β . As shown in Fig. 5 (left panel), km23 was phosphorylated upon co-expression of both types of TGF β receptors (lane 2). A ligand-dependent increase in km23 phosphorylation was observed at 5 and 15 minutes after TGF β treatment (lanes 3 and 4). As shown previously, km23 was not auto-phosphorylated (lane 1), nor was there

phosphorylation in the IgG control lane (lane 5). These results indicate that km23 phosphorylation by TGF β is ligand-dependent.

Since TGF β stimulation increased phosphorylation levels of km23, it was of interest to see whether another growth factor ligand produced a similar effect. Epidermal growth factor (EGF) is known to phosphorylate many downstream targets after activation of its receptor (Jorissen et al, 2003). For example, Shc (Sakaguchi et al, 1998), Src (Mao et al, 1997), STATs (David et al, 1996), PLC- γ (Wahl et al, 1990), and PPAR γ (Camp and Tafuri, 1997) have all been shown to be phosphorylated within 30 minutes of EGF treatment. In order to determine whether km23 could be phosphorylated by EGF, we performed in vivo phosphorylation assays similar to those for TGF β . As shown in Fig. 5 (right panel), EGF did not stimulate km23 phosphorylation during a treatment period of 0-30 minutes (lanes 7-12). EGF has been shown to phosphorylate other substrates during this time period in this cell line (Camp and Tafuri, 1997). As expected, no km23 phosphorylation was observed in the negative control (lanes 6-13). Collectively, our results suggest that km23 phosphorylation may be mediated specifically by TGF β .

We have also previously shown that overexpression of either the activated TGF β receptor complex or RII alone could phosphorylate km23 in COS-1 cells (Tang et al, 2002). However, it was unclear whether co-expression of RI with RII altered km23 phosphorylation by RII. As shown in Fig. 6 the level of ligand-dependent phosphorylation of km23 by RII alone (lanes 7 and 8) was similar to that observed after co-expression of both receptors (lanes 2 and 3). As previously shown, km23

phosphorylation was completely blocked upon expression of KN RII, even after treatment with TGF β (lanes 11 and 12). As expected, co-expression of RI and RII without km23 resulted in no detectable phosphorylation (lane 1). The IgG control (lane 4) was also negative. Thus, phosphorylation of km23 by TGF β can occur in the absence of RI, and the presence of wild-type RI does not alter the ability of RII to phosphorylate km23. These results also confirm the ligand-dependent phosphorylation of km23 in another cell line, COS-1 (Fig. 6, lanes 2 and 3).

In order to address the role of the kinase activity of RI in the TGF β -mediated phosphorylation of km23, *in vivo* phosphorylation assays were performed using various mutant forms of RI and RII alone or in combination. Here, we examined whether a kinase deficient version of RI (KN RI) could block ligand-dependent phosphorylation of km23. By comparison of the bands in lanes 7 and 9, in the absence of TGF β km23 was phosphorylated to a reduced extent after co-expression of RII with KN RI, as opposed to RII alone. In contrast, in the presence of TGF β , KN RI reduced km23 phosphorylation by approximately 3-fold, relative to that observed after expression of RII alone (lanes 8 and 10). As shown in lanes 5 and 6, km23 was not phosphorylated when RI alone was co-expressed with km23. Thus, phosphorylation of km23 by TGF β can occur without the kinase activity of RI, and the presence of wild-type RI does not alter the ability of RII to phosphorylate km23. However, the kinase activity of RI appears to contribute to km23 phosphorylation in some manner.

Our previous data suggested that km23 might function as a "motor receptor" to recruit TGF β signaling complexes to the dynein motor for intracellular transport along MT toward the nucleus (Tang et al, 2002). Since Smad2 is a critical intracellular mediator of TGF β signaling (Macias-Silva et al., 1996; Heldin et al., 1997; Attisano and Wrana, 1998, Massague 1998), and it is co-localized with RII in specific endosome compartments after receptor endocytosis (Hayes et al., 2002). It was conceivable that Smad2 might function as one of the cargo that km23 might recruit. If this was the case, we would expect Smad2 to be co-localized with km23. In order to determine whether this was the case, we performed immunofluorescence studies in TGF β -responsive MDCK cells, using the km23 rabbit antiserum prepared against amino acids 1-13. As indicated in Fig. 7A, in the absence of TGF β treatment, endogenous km23 was present in perinuclear puncta and was partially co-localized with endogenous Smad2. TGF β treatment resulted in a greater co-localized of Smad2 with km23 at both 2(B) and 5(C) minutes after its addition to MDCK cells. In contrast, once Smad2 had translocated to the nucleus by 15 minutes (D), km23 was still localized in the cytoplasm and no longer co-localized. Smad2 would be expected to execute its functions in the transcriptional regulation of gene expression, whereas km23 is likely to be transported to acidic vesicular compartments for degradation. Thus, our results indicate that km23 and Smad2 are co-localized either in the absence of TGF β , or following TGF β treatment for 2 or 5 min, prior to the entry of Smad2 into the nucleus.

Since km23 and Smad2 appeared to be co-localized in the absence of TGF β , but were then separated into distinct cell locales after TGF β treatment, it was of interest

to determine whether km23 could directly interact with Smad2. We performed GST pull-down assays after transfection of Smad2-flag into 293T cells. Cell lysates were incubated with sepharose-bound, bacterially-expressed GST alone or GST-rkm23. An anti-flag Ab was used as the blotting Ab to detect Smad2-flag in the GST-km23 complex. As shown in Fig. 8A, Smad2 was visible in the GST-km23 immunoprecipitates (lane 4), but not in the immunoprecipitates from GST only (lane 3). EV control lanes were also negative (lanes 1, 2). The results indicate that km23 interacts with Smad2 in vitro.

In order to determine whether km23 and Smad2 interacted in vivo, we performed IP/blot analysis after transfection of either EV or km23-Flag. As shown in Fig. 8B, immunoprecipitation of the Smad2 protein using an anti-Smad2 Ab was able to co-IP km23 (lane 2, left panel). In contrast, the EV control was negative (lane 1, left panel). The interaction between Smad2 and Sp1 (Feng et al., 2000, Pardali et al., 2000) is shown as a positive control for comparison (lane 3, right panel). Further, we did not find a direct interaction between Smad2 and DIC (lane 4, right panel), yet the positive control (IP DIC, blot DIC, lane 5, right panel) did reveal the appropriate location of the DIC band. The results clearly demonstrate that km23 interacts with Smad2 under physiological conditions, but that it cannot directly interact with the dynein motor complex.

A noted biological effect of TGF β in epithelial cells is growth inhibition (Piez and Sporn, 1993; Akhurst and Derynck, 2001; Yue and Mulder, 2001). Further, inactivation of Smad2 has been shown to effectively eliminate TGF β -induced growth inhibition, without an apparent effect on the ability of TGF β to induce expression of other genes

(Feng et al., 2002). Since we have shown that km23 interacts with and co-localized with Smad2, it was of interest to determine whether blockade of km23 would lead to a change in the ability of TGF β to inhibit the cell cycle in late G1, as assessed by a change in DNA synthesis. The MDCK cells used for these studies are naturally responsive to the growth inhibitory effects of TGF β , and display an inhibition of [3 H]thymidine incorporation of approximately 90%. Therefore, we transfected MDCK cells with siRNA to disrupt the expression of endogenous km23 using Oligofectamine as described in the "Materials and Methods." Western blot analysis was then performed to determine whether km23 expression was blocked. As shown in Fig. 9A, treatment with either 0.10 μ M or 0.12 μ M siRNA induced a marked decrease (compared to mock-treated cells) in km23 levels at both 24 hours (lanes 1-3) and 48 hours (lanes 4-6) after addition of the siRNA. The decrease in endogenous km23 was maximal at 24 hours after transfection of siRNA (lanes 2 and 3, top panel), with a reduction of km23 expression by approximately 65%. The silencing effect was apparent for at least an additional 24 hours, yet this effect was not enhanced when the siRNA concentration was increased from 0.10 μ M to 0.12 μ M (lanes 2, 3, 5, and 6, top panel). After 72 hours, there was no difference in endogenous km23 levels between the mock-treated and siRNA-treated cells (lanes 7-9, top panel). The bottom panel of Fig. 9A depicts the results of densitometric scans of the top panel, with the percent of control values provided above the relevant bars.

Since 0.1 μ M siRNA resulted in maximal silencing at 24 hours after addition to MDCK cultures, we examined TGF β -mediated inhibition of DNA synthesis of MDCK

cells in the presence and absence of 0.1 μ M siRNA at this time point. The [3 H]thymidine incorporation analyses in Fig. 9B indicate that blockade of endogenous km23 led to a reduction in the ability of TGF β to inhibit DNA synthesis. While TGF β inhibited the DNA synthesis of the mock-treated cells by 92%, cells transfected with km23 siRNA displayed only a 73% inhibition of DNA synthesis by TGF β . Statistical analyses using the Student's t-test revealed that this difference was statistically significant ($p < 0.01$). Together, these results demonstrate that km23 plays a role in TGF β -mediated inhibition of DNA synthesis.

DISCUSSION

We have isolated km23 via its ability to interact with the intracellular portions of the TGF β receptors. Further, we have demonstrated that this TGF β receptor-interacting protein is associated with the TGF β receptor complex through RII (Tang et al., 2002). Here we show that TGF β induced a ligand-dependent increase in km23 phosphorylation, mediated by preferentially by the kinase activity of RII. However, co-expression of a kinase-deficient version of RI with RII decreased km23 phosphorylation relative to that observed after expression of only RII. Thus, the kinase activity of RI also appears to play a role in phosphorylation of km23.

Of greater significance, km23 appeared to be partially required for TGF β -mediated inhibition of thymidine incorporation in MDCK cells. A complete blockade of thymidine incorporation by the km23 siRNA would not be expected, however for two reasons. First, the siRNA blockad of km23 expression was not complete (only 65%). Second, other pathway components are known to be involved in mediating this complex biological response with regard to the latter point, TGF β activation of Ras, extracellular signal-regulated kinases (Erks) and of stress-activated protein kinases/Jun N-terminal kinases (Sapk/JNKs) is known to be required for TGF β -mediated growth inhibition (Mulder and Morris, 1992; Hartsough et al., 1996; Frey and Mulder, 1997; Yue et al., 1998; Yue et al., 1999b; Mulder, 2000). Additional evidence indicate that over-expression of the p65 subunit of the NF- κ B/Rel family in Hs578T cells can abrogate the ability of TGF β to inhibit cell growth (Sovak et al., 1999),

suggesting that TGF β regulation of NF- κ B/Rel activity is also associated with TGF β -mediated growth inhibition. Thus, several TGF β -regulated components appear to be required to mediate the growth inhibitory response to TGF β . km23 may represent a novel member of this group of signaling components.

Subcellular localization of a signaling molecule plays an important role in its ability to function during the transduction of cellular signals. It is essential for a signaling molecule to be in the appropriate cell location at the appropriate time for efficient activation (Whitmarsh and Davis, 2001). Our data indicate that km23 is a TGF β receptor-interacting protein that directly interacts with Smad2 in the cytoplasm under both in vivo and in vitro conditions. Further, km23 co-localizes with Smad2 either in the absence of TGF β , or at early time periods after TGF β addition, suggesting that Smad2 may be one of the cellular cargo that km23 recruits to the dynein complex for intracellular transport along MTs. After 15 minutes of TGF β treatment, however, Smad2 translocates to the nucleus, while km23 remains in the cytosol.

Smads2/3/4 have been shown to be distributed along the MT network (Dong et al. 2000). However, little is known about how Smads transition from the MTs to an activated state. We have shown that km23 is the light chain of dynein, and TGF β leads to the recruitment of km23 to the DIC in a rapid, TGF β -inducible manner (Tang et al. 2002). Based upon our finding that km23 may control the cell localization of TGF β signaling components such as Smad2 in the cytoplasm, it is possible that km23 can transport Smad2 toward the nucleus along the MTs, prior to Smad2's effects on nuclear transcription events.

It has been shown recently via genetic studies in *Drosophila* that a trio of membrane-associated proteins act in a common pathway to regulate epithelial cell polarity and cell growth (Bilder et al., 2000). Since TGF β and its signaling components can function as tumor suppressors, similar to this trio of protein, perhaps km23 contributes to appropriate trafficking of provides TGF β signaling components such as Smad2, thereby maintain cell polarity in the signaling pathway. In this regard, we have provided evidence to suggest that km23 is important for maintain the appropriate localization of TGF β signaling components such as Smad2. It is conceivable that an alteration of km23 might result in a mis-localization of such signaling intermediators, with a concomitant disruption of TGF β growth inhibitory signals. Indeed, an alteration in the homologue to km23 (rob1) resulted in accumulation of cargoes and an increase in mitotic index (Bowman et al; 1999). Our results using km23-specific siRNA suggest that km23 may, indeed, play an important role in TGF β -mediated growth suppression.

ACKNOWLEDGMENTS

We thank J. Wrana (Samuel Luenfeld Research Institute, Toronto, Canada) for pCMV5-HA-TGF β RII and pCMV5-Flag-Smad2; H. Lodish (Massachusetts Institute of Technology, Cambridge, MA) for the RII cDNA; K. Miyazono (University of Tokyo, Japan) for the Alk-5 RI cDNA; H. Moses (Vanderbilt University, Nashville, TN) for the Flag-Smad3; T. W. Wong (Bristol-Myers Squibb, Princeton, NJ) for pFlag-CMV5 and for preparing the RI-pFlag-CMV5 expression construct; and R. Derynck (University of California, San Francisco) for RI-myc. We also thank R.C. Bast Jr. (M.D. Anderson Cancer Center, Houston, TX) for the OVCA 433 cells. This work was supported by National Institutes of Health Grants CA51452, CA90765, CA92889, CA100239, and Dept. of defense awards DAWD 17-01-1-0592 to K.M.M.

REFERENCES

- Akhurst, R. J. and Derynck, R.** (2001). TGF- β signaling in cancer--a double-edged sword. *Trends Cell Biol.* **11**, S44-S51.
- Akopyants, N. S., Clifton, S. W., Martin, J., Pape, D., Wylie, T., Li, L., Kissinger, J.C., Roos, D. S., Beverley, S. M.** (2001). A survey of the *Leishmania major* Friedlin strain V1 genome by shotgun sequencing: a resource for DNA microarrays and expression profiling. *Mol Biochem Parasitol.* **113**, 337-340.
- Attisano, L. and Wrana, J. L.** (1998). Mads and Smads in TGF β signaling. *Curr. Opin. in Cell Biol.* **10**, 188-194.
- Attisano, L. and Wrana, J. L.** (2002). Signal transduction by the TGF- β superfamily. *Science* **296**, 1646-1647.
- Bilder, D., Li, M. and Perrimon, N.** (2000). Cooperative regulation of cell polarity and growth by *Drosophila* tumor suppressors. *Science* **289**, 113-116.
- Camp, H. S. and Tafuri, S. R.** (1997) Regulation of peroxisome proliferator-activated receptor γ activity by mitogen-activated protein kinase. *J. Biol. Chem.* **272**, 10811-10816.

Carpenter, G. (1979) Epidermal growth factor. *Annu. Rev. Biochem.* **48**, 193-230.

Chen, T., Carter, D., Garrigue-Antar, L. and Reiss, M. (1998). Transforming growth factor- β type I receptor kinase mutant associated with metastatic breast cancer.

Cancer Res. **58**, 4805-4810.

Chen, T., Triplett, J., Dehner, B., Hurst, B., Colligan, B., Pemberton, J., Graff, J.R. and

Carter, J.H. (2001a). Transforming growth factor- β receptor type I gene is frequently mutated in ovarian carcinomas. *Cancer Res.* **61**, 4679-4682.

Chen, T., Yan, W., Wells, R. G., Rimm, D. L., McNiff, J., Leffell, D. and Reiss, M.

(2001b). Novel inactivating mutations of transforming growth factor- β type I receptor gene in head-and-neck cancer metastases. *Int. J. Cancer.* **93**, 653-661.

Derynck, R., Akhurst, R. J. and Balmain, A. (2001). TGF- β signaling in tumor suppression and cancer progression. *Nature Genet.* **29**, 117-129.

Dole, V., Jakubzik, C. R., Brunjes, B. and Kreimer, G. (2000). A cDNA from the green alga *Spermatozopsis similis* encodes a protein with homology to the newly discovered Roadblock/LC7 family of dynein-associated proteins. *Biochim Biophys Acta.* **1490**, 125-30.

Dong, C., Li, Z., Alvarez, Jr., R., Feng, X. H. and Goldschmidtch-Clermont, P. J. (2000).

Microtubule binding to Smads may regulate TGF- β activity. *Mol. Cell.* **5**, 27-34.

Feng, X. H. and Derynck, R. (1997). A kinase subdomain of transforming growth factor-beta (TGF- β) type I receptor determines the TGF- β intracellular signaling specificity. *EMBO J.* **16**, 3912-3923.

Feng, X. H., Lin, X. and Derynck, R. (2000). Smad2, Smad3 and Smad4 cooperate with Sp1 to induce p15(Ink4B) transcription in response to TGF- β . *EMBO J.* **19**, 5178-93.

Feng, X. H., Liang, Y.Y., Liang, M., Zhai, W. and Lin, X. (2002). Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF- β -mediated induction of the CDK inhibitor p15(Ink4B). *Mol Cell.* **9**, 133-43.

Fink, S. P., Swinler, S. E., Lutterbaugh, J. D., Massague, J., Thiagalingam, S., Kinzler, K. W., Vogelstein, B., Willson, J. K. and Markowitz, S. (2001). Transforming growth factor- β -induced growth inhibition in a Smad4 mutant colon adenoma cell line. *Cancer Res.* **61**, 256-260.

Frey, R. S. and Mulder, K. M. (1997). Involvement of extracellular signal-regulated kinase 2 and stress-activated protein kinase/Jun N-terminal kinase activation by transforming growth factor β in the negative growth control of breast cancer cells. *Cancer Res.* **57**, 628-633.

Georgatos, S. D., Meier, J. and Simos, G. (1994). Lamins and lamin-associated proteins. *Curr Opin Cell Biol.* **6**, 347-353.

Hartsough, M. T. and Mulder, K. M. (1995). Transforming growth factor β activation of p44mapk in proliferating cultures of epithelial cells. *J. Biol. Chem.* **270**, 7117-7124.

Hartsough, M. T., Frey, R. S., Zipfel, P. A., Buard, A., Cook, S. J., McCormick, F. and Mulder, K. M. (1996). Altered transforming growth factor β signaling in epithelial cells when ras activation is blocked. *J. Biol. Chem.* **271**, 22368-22375.

Hartsough, M. T. and Mulder, K. M. (1997). Transforming growth factor- β signaling in epithelial cells. *Pharmacol. Ther.* **75**, 21-41.

Hayes, S., Chawla, A. and Corvera, S. (2002). TGF β receptor internalization into EEA1-enriched early endosomes: role in signaling to Smad2. *J Cell Biol.* **158**, 1239-1249.

Heldin, C.-H., Miyazono, K. and ten Dijke, P. (1997). TGF- β signalling from cell membrane to nucleus through SMAD proteins. *Nature* **390**, 465-471.

Hocevar, B. A., Brown, T. L. and Howe, P. H. (1999). TGF- β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway. *EMBO J.* **18**, 1345-1356.

Kim S.-J., Im, Y.-H., Markowitz, S. D. and Bang, Y.-J. (2000). Molecular mechanisms of inactivation of TGF- β receptors during carcinogenesis. *Cytokine Growth Factor Reviews* **11**, 159-168.

Macias-Silva, M., Abdollah, S., Hoodless, P.A., Pirone, R., Attisano, L., and Wrana, J.L. (1996). MADR2 is a substrate of the TGF β receptor and its phosphorylation is required for nuclear accumulation and signaling. *Cell* **87**, 1215-1224.

Massague, J. (1998). TGF- β signal transduction. *Ann. Rev. Biochem.* **67**, 753-791.

Massague, J., Blain, S. W. and Lo, R. S. (2000). TGF- β signaling in growth control, cancer, and heritable disorders. *Cell* **103**, 295-309.

Miyazono, K. (2000). TGF- β signaling by Smad proteins. *Cytokine Growth Factor Rev.* **11**, 15-22.

Mulder, K. M. (2000). Role of Ras and Mapks in TGF β signaling. *Cytokine Growth Factor Rev.* **11**, 23-35.

Mulder, K. M. and Morris, S. L. (1992). Activation of p21ras by transforming growth factor β in epithelial cells. *J. Biol. Chem.* **267**, 5029-5031.

Pardali, K., Kurisaki, A., Moren, A., ten Dijke, P., Kardassis, D. and Moustakas, A. (2000). Role of Smad proteins and transcription factor Sp1 in p21(Waf1/Cip1) regulation by transforming growth factor- β . *J Biol Chem.* **275**, 29244-29256.

Peifer, M. (2000). Cell biology. Travel bulletin--traffic jams cause tumors. *Science* **289**, 67-69.

Piez, K. A. and Sporn, M. B. (1993). Transforming growth factor- β : chemistry, biology, and therapeutics. *Ann. NY Acad. Sci.* **593**, 1-377.

Roberts, A. B. (1998). Molecular and cell biology of TGF- β . *Miner Electrolyte Metab.* **24**, 111-119.

Roberts, A. B. and Sporn, M. B. (1990). The transforming growth factors. In *Peptides, Growth Factors and Their Receptors, Part I* (eds. M. B. Sporn and A. B. Roberts), pp. 419-472. Berlin: Springer-Verlag.

Sovak, M. A., Arsura, M., Zanieski, G., Kavanagh, K.T. and Sonenshein, G. E. (1999).

The inhibitory effects of transforming growth factor- β 1 on breast cancer cell proliferation are mediated through regulation of aberrant nuclear factor- κ B/Rel expression. *Cell Growth Differ.* **10**, 537-44.

Sporn, M. B. and Vilcek, J. T. (eds.). (2000). *Cytokine and Growth Factor Reviews - TGF β Special Issue* **11**, 1-168.

Tang, Q., Staub, C.M., Gao, G., Jin, Q., Wang, Z., Ding, W., Aurigemma, R.E., and Mulder, K.M. (2002). A novel transforming growth factor- β receptor interacting protein that is also a light chain of the motor protein dynein. *Mol. Biol. Cell* **13**, 4484-4496.

ten Dijke, P., Miyazono, K. and Heldin, C.-H. (2000). Signaling inputs converge on nuclear effectors in TGF- β signaling. *Trends Biochem. Sci.* **25**, 64-70.

Wall, N. A. and Hogan, B. L. (1994). TGF- β related genes in development. *Curr. Opin. Genet. Dev.* **4**, 517-522.

Wang, D., Kanuma, T., Mizunuma, H., Takama, F., Ibuki, Y., Wake, N., Mogi, A., Shitara, Y. and Takenoshita, S. (2000). Analysis of specific gene mutations in the transforming growth factor- β signal transduction pathway in human ovarian cancer. *Cancer Res.* **60**, 4507-4512.

Watson, K. L., Justice, R. W. and Bryant, P. J. (1994). *Drosophila* in cancer research: the first fifty tumor suppressor genes. *J. Cell Sci. Suppl.* **18**, 19-33.

Whitmarsh, A. J. and Davis R. J. (2001). Signal transduction by target-derived neurotrophins. *Nat Neurosci.* **4**, 963-964.

Yue, J., Buard, A. and Mulder, K. M. (1998). Blockade of TGF β ₃ up-regulation of p27Kip1 and p21Cip1 by expression of RasN17 in epithelial cells. *Oncogene* **17**, 47-55.

Yue, J., Frey, R. S. and Mulder, K. M. (1999a). Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF β . *Oncogene* **18**, 2033-2037.

Yue, J., Hartsough, M. T., Frey, R. S., Frielle, T. and Mulder, K. M. (1999b). Cloning and expression of a rat Smad1: regulation by TGF β and modulation by the Ras/MEK pathway. *J. Cell Physiol.* **178**, 387-96.

Yue, J. and Mulder, K. M. (2000). Requirement of Ras/MAPK pathway activation by transforming growth factor- β for transforming growth factor- β 1 production in a Smad-dependent pathway. *J. Biol. Chem.* **275**, 30765-30773.

Yue, J. and Mulder, K.M. (2001). Transforming growth factor- β signal transduction in epithelial cells. *Pharmacol. Ther.* **91**, 1-34.

Zipfel, P. A., Ziober, B. L., Morris, S. L. and Mulder, K. M. (1993). Up-regulation of transforming growth factor- α expression by transforming growth factor- β 1, epidermal growth factor, and N,N-dimethylformamide in human colon carcinoma cells. *Cell Growth Differ.* **4**, 637-645.

FIGURE LEGENDS

Fig. 1. Alignment of amino acid sequences comparing km23 family members. The coding region for the following km23 family members are aligned to illustrate the relative identities: hkm23-1 (accession # AY026513), ZFIN (accession # AAH46084; 74% homology to hkm23-1), robl (accession # AF141920; 67% homology to hkm23-1), LC7 (accession # AF140239; 59% homology to hkm23-1), T24H10.6 (accession # Z54216; 56% homology to hkm23-1), B15 (accession # AJ243446; 56% homology to hkm23-1), bxd (accession # M27999; 40% homology to hkm23-1), and LMAJFV1 (accession # AQ850960; 33% homology to hkm23-1).

Fig. 2. Northern blot analysis of km23 mRNA expression in several human tissues. Top panel, a human tissue mRNA blot was obtained from BD Bioscience Clontech and was probed with the ^{32}P -labeled cDNA for hkm23. Middle panel, the membrane was reprobed with β -actin as a control. As expected, the primary β -actin band was 2 kb, whereas an additional species of 1.7 kb was observed in heart and skeletal muscle. Bottom panel, plot of densitometric scan of results from top panel after normalization of km23 expression levels against β -actin control levels.

Fig. 3. km23 protein expression was detectable by Western blot analysis using a rabbit polyclonal km23 anti-serum. **A:** TGF β does not modulate the expression of endogenous km23. Left panel, MDCK cells lysates were incubated in serum-free α -

MEM medium for 1 hour prior to treatment with (lanes 2-4) or without (lane 1) TGF β (10 ng/ml). Lysates were analyzed by SDS-PAGE (15%) and transferred to a PVDF membrane. The membrane was then incubated with rabbit polyclonal km23 anti-serum, followed by incubation with an anti-rabbit IgG secondary antibody (1:7500). Right panel, MDCK cells lysates were analyzed as in left panel, except that one lane was incubated with preimmune rabbit serum as a control (lane 2) to demonstrate the specificity of the Ab. **B:** The rabbit km23 polyclonal anti-serum could detect km23 in various species. Top panel, protein lysates (75 μ g) were prepared from 293, FET, OVCAR 433, HepG2, Mv1Lu, and MDCK cells, and analyzed as in A. Equal loading was confirmed by blotting with a DIC Ab (Chemicon).

Fig. 4. TGF β does not cause a translocation of km23 to the nucleus. Mv1Lu cells were either mock transfected or transiently transfected with EV or km23-flag. Twenty-four hours later, cells were treated without (lanes 1-6) or with (lanes 7-12) TGF β (10 ng/ml) for 30 minutes. Cells were then fractionated as described in "Materials and Methods." Top panel, both cytoplasmic and nuclear fractions were subjected to SDS-PAGE (15%), transferred to a PVDF membrane, and blotted with anti-flag. Bottom panel, the membrane was then reprobed with anti-lamin A/C Ab as a nuclear marker.

Fig. 5. Specificity of TGF β -dependent phosphorylation of km23. 293T cells were transiently transfected with either EV, km23-flag, and/or RI-HA and RII-HA as indicated. Twenty-four hours after transfection, cells were labeled for 3 hours with [32 P] in the

absence or presence of TGF β (5 μ g/ml) (left) or EGF (100 ng/ml) (right) for the indicated times. Thereafter, cells were lysed and IP'd with anti-Flag. In vivo phosphorylation of km23-flag was visualized by SDS-PAGE (15%) and autoradiography.

Fig. 6. Role of RI and RII in ligand-dependent phosphorylation of km23. COS-1 cells were transiently transfected with either EV, km23-flag, and/or wild-type or mutant RI and RII as indicated. Twenty-four hours after transfection, cells were labeled for 3 hours with [32 P]_i in the absence or presence of TGF β (10 μ g/ml, 10 minutes), followed by cell lysis and IP with an anti-Flag Ab. Top panel, in vivo phosphorylation of km23-flag was visualized by SDS-PAGE (15%) and autoradiography. Bottom panel, plot of densitometric scans of km23 phosphorylation. km23 expression values from a flag immunoblot (not shown) were used to normalize loading and expression among the lanes.

Fig. 7. km23 colocalizes with Smad2 in TGF β dependant maner. **A:** MDCK cells were fixed, permeabilized, and stained with rabbit km23 anti-serum (left, top row) and mouse anti-Smad2 (left, second row). The overlap and a region from this panel magnified are shown in third row. No signal was detected in the control (right panel). **B:** MDCK cells were fixed, permeabilized, and stained with rabbit km23 anti-serum (left, top row) and mouse anti-Smad2 (left, second row). The overlap and a region from this panel magnified are shown in third row. No signal was detected in the control (right

panel). **B:** MDCK Cells were incubated with TGF β (2.5ng/ml) for 2 minutes, and then cells were fixed, permeabilized, and stained with rabbit km23 anti-serum (left, top row) and mouse anti-Smad2 (left, second row). The overlap and a region from this panel magnified are shown in third row. No signal was detected in the control (right panel). **C:** MDCK Cells were incubated with TGF β (2.5ng/ml) for 5 minutes, and then cells were fixed, permeabilized, and stained with rabbit km23 anti-serum (left, top row) and mouse anti-Smad2 (left, second row). The overlap and a region from this panel magnified are shown in third row. No signal was detected in the control (right panel). **D:** MDCK Cells were incubated with TGF β (2.5ng/ml) for 15 minutes, and then cells were fixed, permeabilized, and stained with rabbit km23 anti-serum (left, top row) and mouse anti-Smad2 (left, second row). The overlap and a region from this panel magnified are shown in third row. No signal was detected in the control (right panel).

Fig. 8. km23 interacts with Smad2 via GST pull-down and IP/blot assays. **A:** Top panel, 293T cells were transfected with either Flag-tagged Smad2 or EV, and lysates were incubated with sepharose bound, bacterially-expressed GST alone or GST-rkm23. GST- bound proteins were analyzed by SDS-PAGE and were immunoblotted with an anti-flag Ab. Smad2 interacts with GST-km23 (lane 4), but not with GST alone (lane 3). EV control lanes (lanes 1, 2) were also negative. Lower panel, Western blot analysis of total cell lysates to confirm expression of Smad2 in the relevant samples prior to assay (lanes 3, 4). **B:** IP/blot analysis of Smad2 interaction with km23. Left panel, Mv1Lu cells were transfected with EV or km23-Flag. Following IP with a Smad2 Ab, lysates were subjected to SDS-PAGE (15%), transferred to a PVDF membrane, and

blotted with an anti-flag Ab. Right panel, Mv1Lu lysates were analyzed by IP/blot, as indicated, to verify the interaction between Smad2 and Sp1 (positive control), but not between Smad2 and DIC (negative control).

Fig. 9. siRNA blockade of km23 expression reduces TGF β -mediated inhibition of DNA synthesis in MDCK cells. **A:** Blockade of endogenous km23 protein expression using siRNA. Top panel, MDCK cells were either mock-transfected or transfected with 0.10 μ M or 0.12 μ M double-stranded siRNA corresponding to nucleotides 77 to 97 of the hkm23 coding region (5'-AAGGCATTCCCATCAAGAGCA-3') as described in "Materials and Methods." After incubation for 24-72 hours, expression levels of endogenous km23 were analyzed via Western blot analysis using rabbit km23 anti-serum (1:500) as described for Fig. 3B. Bottom panel, plot of densitometric results from top panel. km23 levels are shown as a percent of control in parentheses above the relevant bars relative to the corresponding mock-treated values. **B:** The TGF β -mediated repression of [3 H]thymidine incorporation was partially reversed following blockade of endogenous km23 by siRNA. MDCK cells were either mock-transfected or transfected with 0.1 μ M siRNA as described in A. Twenty-four hours after transfection, [3 H]thymidine incorporation analyses were performed as described in "Materials and Methods." The asterisk indicates a statistically significant difference (Student's t-test, $p < 0.01$) in [3 H]thymidine incorporation by TGF β between siRNA-treated and mock-treated MDCK cells.

Fig. 1

hkm23-1	1																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																																										
---------	---	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

hkm23-1	20	I	I	V	V	N	T	E	G	I	P	I	K	S	T	M	D	N	P	T	T	T	Q	Y	A	S	L	M	H	47	
ZFIN	20	I	I	V	V	N	A	E	G	I	P	I	K	S	T	L	D	N	T	S	T	T	V	Q	Y	A	A	N	I	H	47
robl	21	T	I	V	V	N	N	E	G	I	P	V	K	S	T	L	D	N	T	T	T	T	V	Q	Y	A	G	L	M	S	48
LC7	23	I	I	V	I	N	A	E	G	I	A	I	R	T	T	F	D	N	D	L	T	T	V	Q	Y	A	A	L	V	S	50
T24H10.6	20	I	I	V	V	D	S	A	G	R	V	I	H	S	T	I	D	S	D	A	T	A	Q	S	H	T	A	F	L	Q	47
B15	21	T	I	I	I	D	H	N	G	V	T	L	H	S	T	L	D	D	K	T	T	A	E	Y	T	E	L	I	P	48	
bxd	28	V	V	S	D	N	T	A	N	A	V	A	E	T	S	F	D	N	T	S	A	Q	A	I	L	K	H	L	H	55	
LMAJFV1	23	L	H	S	T	H	T	H	T	H	T	K	R	E	E	V	R	T	P	C	T	H	F	L	D	S	A	L	S	50	

hkm23-1	48	S	F	I	L	K	A	R	S	-	T	V	R	D	I	D	P	Q	N	D	L	T	F	L	R	I	R	S	K	74
ZFIN	48	Q	L	L	M	K	A	R	G	-	I	V	R	D	I	D	P	Q	N	D	L	T	F	L	R	V	R	S	K	74
robl	49	Q	L	A	D	R	S	-	-	-	V	V	R	D	L	D	P	S	N	D	M	T	F	L	R	V	R	S	K	73
LC7	51	H	F	T	V	K	A	R	S	-	A	V	R	K	L	D	G	D	N	D	L	K	F	L	R	I	R	S	K	77
T24H10.6	48	Q	L	C	E	K	T	K	T	-	S	I	R	E	L	D	S	S	N	D	L	T	F	L	R	L	R	T	K	74
B15	49	A	L	S	M	L	A	K	N	-	L	V	R	D	V	D	P	Q	N	D	L	D	F	L	R	V	R	S	L	75
bxd	56	G	L	L	V	S	T	C	Q	S	V	V	R	D	I	D	P	S	N	K	L	C	F	M	R	L	G	T	R	83
LMAJFV1	51	M	S	A	S	W	M	K	K	N	M	Y	L	A	I	L	W	P	H	D	L	V	L	I	G	A	Q	P	N	78

hkm23-1	75	K	N	E	I	M	V	A	P	D	K	D	-	-	-	-	Y	F	L	I	V	I	Q	N	P	T	E	96		
ZFIN	75	K	N	E	I	M	I	A	P	D	K	D	-	-	-	-	Y	F	L	I	V	I	Q	N	P	T	E	96		
robl	74	K	H	E	I	M	V	A	P	D	K	D	-	-	-	-	F	I	L	I	V	I	Q	N	P	T	D	K	A	97
LC7	78	K	H	E	I	M	I	A	P	E	F	E	R	S	H	E	Y	Y	L	V	V	V	Q	D	P	S	R	E	A	105
T24H10.6	75	K	N	E	I	M	I	A	P	D	K	D	-	-	-	-	H	V	I	M	V	I	K	D	L	S		95		
B15	76	K	H	E	I	M	V	A	P	K	E	E	-	-	-	-	F	L	L	I	V	I	Q	D	P	A	A	V	98	
bxd	84	K	F	E	Y	L	V	A	P	E	E	Y	-	-	-	-	F	T	I	T	V	V	Q					101		
LMAJFV1	79	E	L	E	L	I	V	A	V	D	L	L	Q	H	-	-	C	L	G	A	H	S	Q	R	L	E	K	C	103	

Fig. 2





Fig. 3

A



B




Fig. 4




Fig. 5




Fig. 6





Fig.7

A.



-TGF β

km23



Preimmuno
serum

Smad2



IgG

merge





Fig.7

B.

+TGF β 2min

km23



Preimmuno
serum



Smad2



IgG



merge



Fig.7


C.

+TGF β 5min


km23




Preimmuno
serum



Smad2



IgG



merge





Fig.7

D.

+TGF β 15min


km23




Preimmuno
serum



Smad2



IgG



merge





Fig. 8

A



B




Fig. 9






Table I: Comparison of hkm23-1 to closely related sequences

<u>Homologue</u>	<u>Species</u>	<u>% homology</u>	<u>% identity</u>	<u>% similarity</u>
rkm23-1	<i>Rattus norvegicus</i>	91	96	98
mkm23-1	<i>Mus musculus</i>	90	95	98
hkm23-2	<i>Homo sapiens</i>	70	77	91
rkm23-2	<i>Rattus norvegicus</i>	71	76	91
mkm23-2	<i>Mus musculus</i>	71	76	91

CURRICULUM VITAE

NAME: KATHLEEN M. MULDER, Ph.D.

TITLE: Professor with tenure

Website:

<http://www.hmc.psu.edu/depts/cgibin/faculty.pl?name=mulder.html&folder=faculty&code=pharmacologydept>

ADDRESS:

Home: 713 W. Elm St.
Palmyra, PA 17078
(717) 832-2203
FAX (717) 832-3450
Cell (717) 512-6560

Work: Dept. of Pharmacology – MC H078
Penn State Univ. College of Medicine
500 University Drive
Hershey, PA 17033
(717) 531-6789
(717) 531-5013 (FAX)

Email: kmm15@psu.edu

EDUCATION:

Muhlenberg College, Allentown, PA

B.S. 1979 Natural Sciences/Math
Psychology

State University of NY at Buffalo, NY

Ph.D. 1985 Pharmacology

APPOINTMENTS:

1980-1984 Graduate Research Assistant, SUNY AB, Buffalo, NY
1985-1988 Research Associate, Department of Pharmacology, Baylor College of Medicine, Houston, TX
1988-1991 Assistant Professor (tenure-track), Department of Pharmacology, Baylor College of Medicine, Houston, TX
1990-1991 Consultant, Bristol-Myers Squibb, Wallingford, CT
1991-1993 Assistant Professor (tenure-track), Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA
1993-1998 Tenured Associate Professor, Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA
1998-Pres Tenured Professor, Department of Pharmacology, Pennsylvania State University College of Medicine, Hershey, PA

AWARDS:

1980-1983 NIH Pre-doctoral Training Grant recipient
1984 First Prize - Sigma XI Research Award Competition
1989-1994 NIH PHS First Independent Research Support and Transition Award: 5.2 percentile
1993-1998 NIH Research Career Development Award (NCI)

CURRENT RESEARCH GRANT SUPPORT (P.I. on all):

R01 CA90765-02; Mechanisms of TGF β Production in Human Cancer Cells;
\$1,200,000 (total direct costs); 04/01/01-03/31/06; 1.8 percentile

R01 CA92889-01; Role of TGF β in Microtubule Dynamics;
\$1,125,000 (total direct costs); 07/01/01-06/30/06

RO1 CA 100239-01; Role of km23 in ovarian cancer; \$1,250,000 (total direct costs);
04/01/03-03/31/08; 1.7 percentile

DOD Ovarian cancer, Development of km23-based diagnostics and therapeutics;
Recommended for funding 12/16/02 (98 percentile; 1.3 priority score); \$526,875
04/15/03-04/14/06

CURRENT RESEARCH GRANT SUPPORT (Consultant)

R01 HD33852-05 (McAllister, PI); 17 α -Hydroxylase Expression in Human Ovarian Cells;
\$175,000 (total direct costs); 07/01/01-06/30/06

PENDING GRANTS (P.I. on all)

Equipment Supplement: Tumor-Host Interactions; \$500,000 (total direct costs); 09/03-09/04

NIH Structural Studies Supplement: High-Resolution NMR Structure of km23 Proteins;
\$40,000 (total direct costs); 11/03-10/04

Grants Completed (P. I. on all):

BC 996476 (DOD Concept Award); Mechanism of Ras Activation by TGF β ;
\$50,000 (total direct costs); 05/01-06/03.

R01 CA51452-12; Mechanisms of TGF β Signaling;
\$627,683 (total direct costs – last 3 years only); 04/89-03/03.

R01 CA68444 Intracellular Mediators of TGF β Effects;
\$545,880 (total direct costs); 04/96-04/01.

R01 CA54816 Role of MAPK's in TGF β -Mediated Cellular Responses;
\$632,878 (total direct costs- 3 years only); 07/92 - 06/01.

5 K04 CA59552 Mediators of Growth Factor Independence in Colon Cancer.
\$345,573 (total direct costs); 05/93-04/98.
Research Career Development Award, National Cancer Institute

PATENT PENDING: Control of TGF β signaling by km23 superfamily members

PEER REVIEW SERVICE

Grants:

NCDDG Grant Review - 10/89
NIH Program Grant Site Visits- 6/90, 3/94, 9/95
NIH R13 Grant Review - 12/90, 12/96
VA Merit Review Applic. - 3/92, 9/92, 8/95
Institutional Research Grant Review Committee - 3/93-present
Israel Science Foundation - 5/93
National Cancer Institute of Canada, Program Project Site Visit - 10/93
American Cancer Society, Local Chapter - 10/94-present
Active Member, NIH Special Study Section SSS2 - 11/94-11/96
NIH R03/RFA Study Section - 3/95
USAMRMC Breast Cancer Reviews - 11/95, 9/96, 9/97, 9/98, 8/99
North Carolina Biotech Center - 4/96
Ad Hoc Member, Metabolic Pathology Study Section, NIH - 6/96-3/97
National Science Foundation - 9/97
Regular Member, Metabolic Pathology Study Section, NIH - 6/97-7/01
Reviewer, NCI Phased Application Awards/SBIR-STTR Initiative,
Cancer Prognosis & Prediction, 10/02
Consultant, for NCI Phased Application Awards, SBIR-STTR Initiative,
Cancer Prognosis & Prediction, 10/02
Reviewer, Tobacco Settlement Research Funds RFA, PSCOM, 4/03

Manuscripts:

Reviewer for:

American Journal of Pathology
American Journal of Physiology
Cancer Chemotherapy and Pharmacology
Cancer Communications/Oncology Research
Cancer Detection and Prevention
Cancer Research
Cell Growth and Differentiation
EMBO Journal
Experimental Cell Research
Gastroenterology
International Journal of Cancer
Journal of Biological Chemistry
Journal of Cellular Physiology
Journal of Cell Science
Journal of Clinical Endocrinology and Metabolism
Molecular Biology of the Cell
Molecular Pharmacology
Oncogene

Editorial Board Member: The Journal of Biological Chemistry, 07/01/01-06/30/06

PROFESSIONAL AFFILIATIONS

American Association for Cancer Research
American Association for the Advancement of Science
Women in Cancer Research
Federation of American Societies for Experimental Biology
American Society for Biochemistry and Molecular Biology
American Society for Cell Biology

INVITED SPEAKER

Albert Einstein School of Medicine, Bronx, NY	1988
National Institute of Environmental Health Sciences, Chapel Hill, NC	1988
Bristol-Myers Co., Wallingford, CT	1988
University of Maryland, Baltimore, MD	1989
University of Tennessee, Memphis, TN	1989
Bristol-Myers Co., Wallingford, CT	1989
Northwestern University School of Medicine, Chicago, IL	1990
M.D. Anderson Cancer Center, Houston, TX	1990
University of Connecticut Health Center, Farmington, CT	1990
University of Alabama College of Medicine, Birmingham, AL	1990
Triton Biosciences, Oakland, CA	1990
Univ. of North Dakota School of Medicine, Grand Forks, ND	1990
Dartmouth Medical School, Hanover, NH	1990
Cell and Molecular Biology Program, Penn State College of Medicine, Hershey, PA	1991
Medical College of Wisconsin Cancer Center, Milwaukee, WI	1992
Case Western Reserve University, Cleveland, OH	1992
Michigan Cancer Foundation, Detroit, MI	1992
Medical College of Ohio, Toledo, OH	1992
Chicago Medical School, North Chicago, IL	1992
Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, PA	1992
Division of Endocrinology, Department of Medicine, Penn State College of Medicine, Hershey, PA	1992
Istituto Nazionale per la ricerca Sul Cancro, Genova, Italy	1992
Bloomsburg University, Bloomsburg, PA	1992
Roswell Park Cancer Institute, Buffalo, NY	1993
Symposium of the American Gastroenterological Assoc., Vail, CO	1994
Bristol Myers Squibb, Princeton, NJ	1994
Fifth International Congress on Anti-Cancer Chemotherapy, Paris, France	1995
Division of Endocrinology, Department of Medicine, Penn State College of Medicine, Hershey, PA	1995
Department of Biological Chemistry and Molecular Biology, Penn State College of Medicine, Hershey, PA	1995
Cancer Research Center of Hawaii, Honolulu, HI	1995
Bowman Gray Medical School of Wake Forest Univ., Winston-Salem, NC	1995

University of Miami Medical Center, Miami, FL	1995
Division of Endocrinology, Department of Medicine, Penn State College of Medicine, Hershey, PA	1996
Department of Cellular and Molecular Physiology, Penn State College of Medicine, Hershey, PA	1996
AACR Special Conference: Cell Signaling and Cancer Treatment, Telfs-Buchen, Austria	1997
Penn State University Cancer Center, Hershey, PA	1997
National Cancer Institute, Biological Carcinogenesis and Development Program, Frederick, MD	1997
Onyx Pharmaceuticals, Inc., Richmond, CA	1997
Indiana University Cancer Center, Indianapolis, IN	1997
Creative BioMolecules, Inc, Boston, MA	1998
Baylor College of Medicine, Houston, TX	1998
Department of Microbiology & Immunology, Penn State College of Medicine, Hershey, PA	1998
University of Arizona at Tucson, Tucson, AZ	1998
Division of Endocrinology, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, PA	1999
Laboratory of Cell Regulation and Carcinogenesis, NIH, Bethesda, MD	1999
Lombardi Cancer Center, Georgetown University Medical Center, Washington, D.C.	1999
TGF β : Biological Mechanisms and Clinical Applications; 3rd Inter. Conf., National Institutes of Health, Bethesda, MD	1999
Session Chair, AACR Mini-symposium, Cell Signaling thru the Cytoplasm	2000
Program in Genetics, Pennsylvania State University, University Park, PA	2000
MD Anderson Cancer Center, Houston, TX	2000
Division of Surgery, Department of Medicine, Penn State College of Medicine, Hershey, PA	2000
MCP - Hahnemann School of Medicine, Philadelphia, PA	2001
Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA	2001
11 th International Conference on Second Messengers and Phosphoproteins: 2 nd Messengers, Melbourne, Australia	2001
Southern Research Institute, Birmingham, AL	2001
Virginia Commonwealth University, Richmond, VA	2001
Medical College of Ohio, Toledo, OH	2001
University of Alabama at Birmingham Cancer Center	2001
FASEB Summer Research Conference, Tucson, AZ	2001
MD Anderson Cancer Center, Houston, TX	2001
Duke University School of Medicine, Durham, NC	2001
Penn State University, University Park, PA	2002
Penn State Cancer Institute, Hershey, PA	2002
University of Texas, San Antonio, TX	2003
AACR Annual Meeting, Toronto, CA	2003

TEACHING EXPERIENCE

Graduate Courses - Division of Molecular Biology, Department of Pharmacology
Baylor College of Medicine, 1988-1990

Polypeptide Growth Factors and Their Receptors: Transforming Growth Factor-beta (TGF- β)-Structure and Cellular Effects, Receptor/Ligand Interaction and Associated Events
Oncogenes and Growth Control: Nuclear Oncogenes and Regulatory Factors, Regulation of c-myc Expression in Normal and Transformed Cells

Graduate Courses - Penn State University College of Medicine

Pharmacology 501: Tyrosine Kinase Receptor Signaling, Serine/Threonine Kinase Receptor Signaling

Pharmacology 502: Growth Factors, Oncogenes, and Cell Cycle in Cancer

Molecular Pharmacology Techniques

Reproductive Hormones: Inhibins, Activins, and Follistatins: Endocrine/Paracrine/Autocrine Regulators of the Reproductive System

The Biology of Neoplasia: Growth Factor/Cytokine Signal Transduction Pathways

Cell Communication: Growth Factors, Receptors, and Signal Transduction

Core Cell Biology, CMBIO 540: Actin Microfilaments

Microtubules

Intermediate Filaments

Serine/Threonine Receptor Kinase Signaling

Medical Pharmacology Course

Teaching Committee, Baylor College of Medicine, 1989-1991

Lectures: Adrenergic Drugs, Penn State Univ. College of Medicine, 1991-1993

INSTITUTIONAL COMMITTEE SERVICE

Student Affairs Committee, Baylor College of Medicine, 1988-1991

Medical Pharmacology Teaching Committee, Baylor College of Medicine, 1989-1991

Summer Medical and Research Training Program, Baylor College of Medicine, 1989-1991

Graduate Faculty, Penn State University College of Medicine, 1991-present

Library Advisory Committee, Penn State University College of Medicine, 1991-present

Medical Student Selection Committee, Penn State University College of Medicine, 1992-1995

Pharmacology Faculty Search Committee, Penn State University College of Medicine, 1993-present

Medical Student Curriculum Committee, Penn State University College of Medicine, 1995-1998

Summer Symposium in Molecular Biology, Penn State University, University Park, 1996-present

Faculty Member, Life Sciences Consortium, Graduate Program in Integrative Biosciences, Penn State University, College of Medicine, 1996-present

Faculty Member, Penn State University Graduate Programs:

Pharmacology, 1991-present

Cell and Molecular Biology, 1992-present

MD/PhD Program, 1995-present

Molecular Medicine, 1996-present

Chemical Biology, 1999-present
 Cellular and Molecular Mechanisms of Toxicity/Molecular Toxicology, 1999-present
 Genetics, 1999-present
 Chair - Appointment, Promotion, Tenure Committee, Dept. of Pharmacology, PSU College of Medicine, 2001- present
 Co-Chair, Seminar Committee, Dept. of Pharmacology, PSCOM, 2001-present
 Member, Education Committee, PSCOM Cancer Institute, 2001-present
 Member, Search Committee for Director, PSCOM Cancer Institute, 2002-2003
 Member, Search Committee for Director, Gittlen Cancer Research Institute, 2003-present

NEWS RELEASES ABOUT RESEARCH FROM THE MULDER LAB

09/04/2002	Penn State Newswire	Study finds new target for development of anti-cancer drugs
09/04/2002	Penn State College of Medicine News Release	Study finds new target for development of anti-cancer drugs: Protein found effective in nearly half of human cancer tissues
09/11/2002	Hummelstown Sun	Anti-Cancer Target
09/12/2002	Espicom Business Intelligence	New target for anticancer therapies identified
09/27/2002	Central Penn Business Journal	Help for Cancer

PUBLICATIONS

1. Roth, J.A., Eddy, B.J., Pearce, B., and **Mulder, K.M.**: Phenylhydrazine: Selective inhibition of human brain type B monoamine oxidase. *Biochem. Pharmacol.*, 30:945-950, 1981.
2. **Mulder, K.M.**, and Kostyniak, P.J.: Stabilization of glutathione in urine and plasma: Relevance to urinary metal excretion studies. *J. Anal. Toxicol.*, 9:31-35, 1985.
3. **Mulder, K.M.**, and Kostyniak, P.J.: Involvement of glutathione in the enhanced renal excretion of methyl mercury in CFW Swiss mice. *Tox. Appl. Pharmacol.*, 78:451-457, 1985.
4. **Mulder, K.M.**, and Kostyniak, P.J.: Effect of L-(alpha-S,5S)-alpha-amino-3-dichloro-4,5-dihydro-5-isoxazoleacetic acid on urinary excretion of methyl mercury in the mouse. *J. Pharmacol. Expt. Ther.*, 234:156-160, 1985.
5. **Mulder, K.M.**, Levine, A.E., Hernandez, X., McKnight, M.K., Brattain, D.E., and Brattain, M.G.: Modulation of c-myc by transforming growth factor- β in human colon carcinoma cells. *Biochem. Biophys. Res. Commun.*, 150:711-716, 1988.

6. **Mulder, K.M.**, and Brattain, M.G.: Alterations in c-myc expression in relation to maturational status of human colon carcinoma cells. *Int. J. Cancer*, 42:64-70, 1988.
7. **Mulder, K.M.**, McKnight, M.K., Hoosein, N.M., Levine, A.E., Hernandez, X., Brattain, D.E., and Brattain, M.G.: Characterization of TGF- β -resistant subclones isolated from a TGF- β -sensitive human colon carcinoma cell line. *Cancer Res.*, 48:7120-7125, 1988.
8. **Mulder, K.M.**, and Brattain, M.G.: Continuous maintenance of transformed fibroblasts under reduced serum conditions: Utility as a model system for investigating growth factor-specific effects in non-quiescent cells. *J. Cell. Physiol.*, 138:450-458, 1989.
9. Hoosein, N.M., McKnight, M.K., Levine, A.E., **Mulder, K.M.**, Childress, K.E., Brattain, D.E., and Brattain, M.G.: Differential sensitivity of subclasses of human colon carcinoma cell lines to the growth inhibitory effects of transforming growth factor- β . *Exp. Cell Res.*, 181:442-453, 1989.
10. **Mulder, K.M.**, and Brattain, M.G.: Growth factor expression and response in human colon carcinoma cells: In: *The Cell and Molecular Biology of Colon Cancer* (Augenlicht, L., ed.), CRC Press: Boca Raton, FL, pp. 45-67, 1989.
11. **Mulder, K.M.**, Levine, A.E., and Hinshaw, X.H.: Up-regulation of c-myc in a transformed cell line approaching stationary phase growth in culture. *Cancer Res.*, 49:2320-2326, 1989.
12. **Mulder, K.M.**, and Brattain, M.G.: Effects of growth stimulatory factors on mitogenicity and c-myc expression in poorly-differentiated and well-differentiated human colon carcinoma cells. *Mol. Endocrinol.*, 3:1215-1222, 1989.
13. **Mulder, K.M.** and Childress-Fields, K.E.: Characterization of a serum-free culture system comparing growth factor requirements of transformed and untransformed cells. *Exp. Cell Res.*, 188:254-261, 1990.
14. **Mulder, K.M.**, Humphrey, L.E., Choi, H.-G., Childress-Fields, K.E., and Brattain, M.G.: Evidence for c-myc in the signaling pathway for TGF- β in well-differentiated human colon carcinoma cells. *J. Cell. Physiol.*, 145:501-507, 1990.
15. **Mulder, K.M.**, Zhong, W., Choi, H.-G., Humphrey, L.E., and Brattain, M.G.: Inhibitory effects of transforming growth factor- β_1 on mitogenic response, transforming growth factor- α , and c-myc in well-differentiated human colon carcinoma cells. *Cancer Res.*, 50:7581-7586, 1990.
16. **Mulder, K.M.**: Differential regulation of c-myc and TGF- α mRNA expression in poorly-differentiated and well-differentiated colon carcinoma cells during the establishment of a quiescent state. *Cancer Res.*, 51:2256-2262, 1991.
17. Wu, S.P., Theodorescu, D., Kerbel, R.S., Willson, J.K.V., **Mulder, K.M.**, Humphrey, L.E., and Brattain, M.G.: TGF- β_1 is an autocrine negative growth regulator of human colon carcinoma FET cells *in vivo* as revealed by transfection of an anti-sense expression vector. *J. Cell. Biol.*, 116:187-196, 1992.
18. **Mulder, K.M.** and Morris, S.L. Activation of p21^{ras} by transforming growth factor β in epithelial cells. *J. Biol. Chem.*, 267:5029-5031, 1992.
19. Brattain, M.G., **Mulder, K.M.**, Wu, S.P., Howell, G., Sun, L., Willson, J.K.V., and Ziober, B.L. Altered expression of transforming growth factor- α and transforming growth factor- β autocrine loops in cancer cells. *Adv. Molec. Cell Biol.* 7:35-59, 1993.
20. **Mulder, K.M.**, Segarini, P.R., Morris, S.L., Ziman, J.M., and Choi, H.G.: Role of receptor complexes in resistance or sensitivity to growth inhibition by TGF β in intestinal epithelial cell clones. *J. Cell. Physiol.* 154:162-174, 1993.

21. Zipfel, P.A., Ziober, B.L., Morris, S.L., and **Mulder, K.M.**: Up-regulation of TGF α expression by TGF β ₁, EGF, and DMF in human colon carcinoma cells. *Cell Growth Differen.* 4:637-645, 1993.
22. Brattain, M.G. and **Mulder, K.M.**: Therapeutic approaches for colon cancer based on transcriptional regulation of specific growth factors. In *Cancer Therapy: Differentiation, Immunomodulation, and Angiogenesis*, edited by N. D'Alessandro, E. Mihich, L. Rausa, H. Tapiero, and T. Tritton. The NATO ASI series H, Cell Biol. 75:51-70, 1993.
23. Zhou, G.H.K., Sechrist, G.L., Brattain, M.G., and **Mulder, K.M.**: Clonal heterogeneity of the sensitivity of human colon carcinoma cell lines to TGF β isoforms. *J. Cell. Physiol.* 165:512-520, 1995.
24. Hartsough, M.E. and **Mulder, K.M.**: Transforming growth factor β activation of p44^{mapk} in proliferating cultures of epithelial cells. *J. Biol. Chem.* 270:7117-7124, 1995.
25. Zhou, G.H.K., Sechrist, G.L., Periyasamy, S., Brattain, M.G., and **Mulder, K.M.**: Transforming growth factor β isoform-specific differences in interactions with type I and II transforming growth factor β receptors. *Cancer Res.* 55:2056-2062, 1995.
26. Buard, A., Zipfel, P.A., Frey, R.S. and **Mulder, K.M.**: Maintenance of growth factor signaling through Ras in human colon carcinoma cells containing K-ras mutations. *Int. J. Cancer* 67:539-546, 1996.
27. Hartsough, M.T., Frey, R.S., Zipfel, P.A., Buard, A., Cook, S.J., McCormick, F. and **Mulder, K.M.**: Altered TGF β signaling in epithelial cells when Ras activation is blocked. *J. Biol. Chem.* 271:22368-22375, 1996.
28. Frey, R.S. and **Mulder, K.M.**: Involvement of ERK2 and SAPK/JNK activation by TGF β in the negative growth control of breast cancer cells. *Cancer Res.*, 57:628-633, 1997.
29. Hartsough, M.T. and **Mulder, K.M.** TGF β signaling in epithelial cells. *Pharmacol. and Ther.*, 75:21-42, 1997.
30. Frey, R.S. and **Mulder, K.M.** TGF β regulation of mitogen-activated protein kinases in human breast cancer cells. *Cancer Lett.*, 117:41-50, 1997.
31. Yue, J., Buard, A., and **Mulder, K.M.** Blockade of TGF β up-regulation of p27^{Kip1} and p21^{Cip1} by expression of RasN17 in epithelial cells. *Oncogene.* 17:47-55, 1998.
32. Liu, X., Yue, J., Frey, R.S., Zhu, Q. and **Mulder, K.M.** TGF β signaling through Smad1 in human breast cancer cells. *Cancer Res.*, 58:4752-4757, 1998.
33. Yue, J., Frey, R.S. Hartsough, M.T., Frielle, T., and **Mulder, K.M.** Cloning and expression of a rat Smad1: Regulation by TGF β and modulation by the Ras/MEK pathways. *J. Cell. Physiol.*, 178:387-396, 1999.
34. Yue, J., Frey, R.S., and **Mulder, K.M.** Cross-talk between the Smad1 and Ras/MEK signaling pathways for TGF β . *Oncogene*, 18:2033-2037, 1999.
35. **Mulder, K.M.** Role of Ras/Mapk pathways in TGF β signaling. *Cytokine & Growth Factor Reviews* 11:23-35, 2000.
36. Yue, J. and **Mulder, K.M.** Activation of the mitogen-activated protein kinase pathways by transforming growth factor- β . In Howe, P. (Ed.): *Transforming Growth Factor Beta Protocols*. The Humana Press, Inc. 142:125-131, 2000.
37. Yue, J. and **Mulder, K.M.** Requirement of Ras/MAPK pathway activation by TGF β for TGF β ₁ production in a Smad-dependent pathway. *J. Biol. Chem.* 275:30765-30773, 2000.
38. Yue, J. and **Mulder, K.M.** Transforming growth factor-beta signal transduction in epithelial cells. *Pharmacology & Therapeutics*, 91:1-34, 2001.

39. Tang, Q., Staub, C., Gao, G., Jin, Q., Wang, Z., Ding, W., Aurigemma, R., and **Mulder, K.M.** A novel transforming growth factor- β receptor-interacting protein that is also a light chain of the motor protein dynein. *Mol. Biol. Cell*, 13: 4484-4496, 2002.
40. Yue, J., Sun, B., Liu, G., and **Mulder, K.M.** Requirement of TGF β receptor-dependent activation of c-Jun N-terminal kinases (JNKs)/Stress-activated protein kinases (Sapks) for TGF β up-regulation of the urokinase-type plasminogen activator receptor. Submitted, 2003.
41. Jin, Q., Staub, C.M., Tang, Q., Ding, W., Gao, G., and **Mulder, K.M.** Role of km23 co-localized and interacted with Smad2 in TGF β -mediated effects. *J. Cell Sci.*, Submitted, 2003.
42. Mulder, K.M. A new target for the development of anti-cancer diagnostics and therapeutics. *Amer. Clin. Lab.*, In Preparation, 2003.
43. Ding, W., Charboneau, L., Espina, V., Liotta, L.A., and Mulder, K.M. A TGF β receptor-interacting protein frequently mutated in epithelial ovarian cancer. *Cancer Res.*, In Preparation, 2003.
44. Ding, W. and Mulder, K.M. Targeting km23 in human cancers. In *Molecular Targeting and Signal Transduction. Molecular Therapeutics*. Ed, Kumar, R. Kluwer Academic Publishers, Cancer Treatment and Research Book Series, In Preparation, 2004.

SELECTED ABSTRACTS

1. **Mulder, K.M.**, Rickling, S., Levine, A.E., and Brattain, M.G.: Effect of differentiation agents on c-myc expression in transformed fibroblasts and in human colon carcinoma cells. *Fed. Proc.*, 45:1707, 1986.
2. **Mulder, K.M.**, and Brattain, M.G.: Loss of cell contact-mediated c-myc regulation in chemically transformed fibroblasts is restored by N,N-dimethylformamide (DMF) and retinoic acid (RA). *J. Cell Biochem. (Suppl.)* 11A:76, 1987.
3. Brattain, M.G., Hoosein, N., Boyd, D., **Mulder, K.**, Levine, A.E., Watkins, L., Chakrabarty, S., Ramey, M.K., and Brattain, D.E.: Regulation of growth in colon carcinoma. *J. Cell. Biochem. (Suppl.)* 11D, 91, 1987.
4. **Mulder, K.M.**, Hernandez, X., Gee, A., and Brattain, M.G.: Transforming growth factor- β (TGF- β) organizes the growth pattern of murine embryonic fibroblasts adapted to growth in low serum. *Fed. Proc.*, May, 1988.
5. McKnight, K., **Mulder, K.**, and Brattain, M.G.: Differences in growth factor sensitivity by well differentiated and poorly differentiated colon carcinomas. *Proc. AACR*, 19:132, 1988.
6. **Mulder, K.M.**, Lynch, M.J., Childress-Fields, K.E., Hinshaw, X.H., Ramey, M.K., and Brattain, M.G.: Transforming growth factor β inhibition of growth factor-stimulated mitogenesis and c-myc expression in human colon carcinoma cells under serum-free conditions. *UCLA Symposia*, January, 1989.
7. Miller, G.S., Hinshaw, X.H., and **Mulder, K.M.**: Modulation of TGF- α secretion in human colon carcinoma cells. *Proc. AACR*, 30:74, 1989.
8. **Mulder, K.M.**: Differential regulation of c-myc and TGF- α expression in poorly-differentiated colon carcinoma cells during the establishment of a quiescent state. 15th International Cancer Congress, Hamburg, Germany, 1990.
9. **Mulder, K.M.**, Morris, S.L., Choi, H.G., Ziman, J., and Segarini, P.R.: Isolation and characterization of intestinal epithelial cell clones displaying hypersensitivity or resistance

- to growth inhibition by transforming growth factor-beta (TGF- β). 1991 Keystone Symposia, Steamboat Springs, CO.
10. **Mulder, K.M.**, Morris, S.L., Choi, H.G., Ziman, J., and Segarini, P.R.: Resistance and hypersensitivity to transforming growth factor- β (TGF- β) in chemically mutagenized intestinal epithelial cells. *Proc. AACR*, 32:42, 1991.
 11. **Mulder, K.M.**, and Morris, S.L.: Activation of p21^{ras} by transforming growth factor β in epithelial cells. 1992 Keystone Symposia, Keystone, CO.
 12. **Mulder, K.M.**, and Morris, S.L.: Transforming growth factor- β stimulates formation of an active p21^{ras}. GTP complex in epithelial cells. *Proc. AACR*, San Diego, CA, May, 1992.
 13. Zipfel, P.Z., Ziober, B.L., Morris, S.L., and **Mulder, K.M.**: Up-regulation of TGF α mRNA and protein by EGF, TGF β_1 , and DMF in human colon carcinoma cells. 11th Summer Symposium in Molecular Biology, Cell Growth and Regulation, Pennsylvania State University, University Park, PA., July 1992.
 14. Hartsough, M.T., Sechrist, G.L., Zhou, G.H., Brattain, M.G., and **Mulder, K.M.**: Differential binding to TGF β receptor subtypes in clonal variants with differential sensitivities to TGF β isoforms. 11th Summer Symposium in Molecular Biology, Cell Growth & Regulation, Pennsylvania State University, University Park, PA, July 1992.
 15. Brattain, M.G., and **Mulder, K.M.**: Therapeutic approaches for colon cancer based on transcriptional regulation of specific growth factors. NATO Advanced Study Institute; Specific Approaches in Cancer Therapy: Differentiation, Immunomodulation and Angiogenesis. Erice, Italy, October 1992.
 16. Hartsough, M.T. and **Mulder, K.M.**: MAPK and PKC involvement in the signaling pathway for TGF β in colon carcinoma and intestinal epithelial cells. Academic Development Program Symposium, Merck Research Labs, Rahway, NJ, October, 1993.
 17. Zipfel, P.A., Buard, A., and **Mulder, K.M.**: Analysis of K-ras point mutations and growth factor activation of p21^{ras} in human colon carcinoma and intestinal epithelial cell lines. *AACR*, San Francisco, CA, April, 1994.
 18. **Mulder, K.M.**: TGF β signaling in colon carcinoma and intestinal epithelial cells. Peptide growth factors in the GI tract. Amer. Gastroenterological Assoc., Vail, CO, June, 1994.
 19. Hartsough, M.T. and **Mulder, K.M.**: TGF β activation of p44^{mapk} in proliferating cultures of intestinal epithelial cells. *AACR*, Toronto, Canada, March, 1995.
 20. Zipfel, P.A. and **Mulder, K.M.**: Altered growth factor activation of Ras in human colon carcinoma cells with K-ras mutations. *FASEB*, Atlanta, GA, April, 1995.
 21. **Mulder, K.M.** and Hartsough, M.T.: TGF β activation of ERK1 in proliferating cultures of intestinal epithelial cells. Fifth International Congress on Anti-Cancer Chemotherapy, Paris, France, February, 1995.
 22. Hartsough, M.D. and **Mulder, K.M.**: Transforming growth factor- β activation of p44^{mapk} in proliferating intestinal epithelial cells. *Proc. AACR Meeting*, Washington, DC, April, 1996.
 23. Hartsough, M.T., Zipfel, P.A., Buard, A., Cook, S.J., McCormick, F., and **Mulder, K.M.**: Requirement of Ras for TGF β -induced activation of extracellular signal-regulated kinase-1 (Erk1) and inhibition of cyclin-dependent kinase-2 (Cdk2) in epithelial cells. Keystone Symposia on Molecular and Cellular Biology, Tamarron, CO, January, 1996.
 24. Frey, R.S. and **Mulder, K.M.**: TGF β regulation of ERK2 and SAPK/JNK activation in the negative growth control of breast cancer cells. *FASEB*, New Orleans, LA, April, 1997.

25. Hartsough, M.T., Frey, R.S., Zipfel, P.A., Buard, A., Cook, S.J., McCormick, F., and **Mulder, K.M.**: TGF β signaling in epithelial cells. AACR Special Conference: Cell Signaling and Cancer Treatment, Telfs-Buchen, Austria, February, 1997.
26. Yue, J., Buard, A., and **Mulder, K.M.**: Blockade of TGF β_3 Up-regulation of p27^{Kip1} and p21^{Cip1} by Expression of RasN17 in Intestinal Epithelial Cells. Keystone Symposium on Molecular and Cellular Biology, Keystone, CO, April, 1997.
27. Frey, R.S., Yue, J., Zhu, Q., Fletcher, T.M., Liu, X., and **Mulder, K.M.**: TGF β signaling and cross-talk between the Smad and Ras Mapk Signaling Cascades in Epithelial Cells. AACR. New Orleans, LA, 1998.
28. Liu, X., Yue, J., Frey, R.S., Zhu, Q., and **Mulder, K.M.**: TGF β signaling through Smad1 in human breast cancer cells. Gordon Conference on Peptide Growth Factors, Meridan, NH, 1998.
29. Yue, J., Frey, R.S., and **Mulder, K.M.**: Cross-talk between the Smad1 and Ras/MEK signaling pathway for TGF β . Gordon Conference on Peptide Growth Factors, Meridan, NH, 1998.
30. Liu, X.J. and **Mulder, K.M.**: The effects of mutation of erk consensus phosphorylation sites (4SP/AP) in Smad1 on TGF β signaling. AACR Annual Meeting; Philadelphia, PA, April, 1999.
31. Yue, J. and **Mulder, K.M.**: Requirement of the Ras pathway for TGF β autoinduction. Annual Meeting of American Society for Biochem. and Molec. Biol., San Francisco, CA, May, 1999.
32. Liu, X. and **Mulder, K.M.** Role of Erk consensus phosphorylation sites in Smad1 on TGF β -mediated responses. TGF- β : Biological Mechanisms and Clinical Applications, 3rd International Conference, Bethesda, MD, 1999.
33. Yue, J. and **Mulder, K.M.** Requirement of Ras, SAPK/JNK, and Erk for TGF β_1 autoinduction in a Smad4 independent pathway. TGF- β : Biological Mechanisms and Clinical Applications, 3rd International Conference, Bethesda, MD, 1999.
34. **Mulder, K.M.** TGF β activation of Ras/Mapks/Sapks: Biological significance for TGF β autoinduction and Smad signaling. AACR Annual Meeting, San Francisco, CA, April 1, 2000.
35. Staub, C.M., Tang, Q., Charboneau, L., Liotta, L.A., and **Mulder, K.M.** km23: Role in TGF β signaling and alterations in human ovarian cancer. AACR Annual Meeting, New Orleans, LA, March, 2001.
36. Tang, Q., Staub, C.M., and **Mulder, K.M.** Identification of a TGF β signaling component that interacts with dynein molecular motors. ASBMB Annual Meeting, Orlando, FL, April, 2001.
37. Tang, Q., Staub, C.M., and **Mulder, K.M.** km23: A novel TGF β receptor-associated protein that interacts with dynein molecular motors. 2nd Messengers: 11th International Conference on Second Messengers and Phosphoproteins, Melbourne, Australia, April, 2001.
38. **Mulder, K.M.** km23: A TGF β signaling intermediate that interacts with the molecular motor dynein. FASEB Summer Research Conference: The TGF β Superfamily: Signaling and Development, July 7-12, 2001.
39. Tang, Q., Staub, C.M. and **Mulder, K.M.** km23: A TGF β signaling intermediate that interacts with dynein. 55th Annual Meeting and Symposium of the Society of General Physiologists, Molecular Motors, Marine Biological Laboratory, Woods Hole, Massachusetts, September, 2001.

Physiologists, Molecular Motors, Marine Biological Laboratory, Woods Hole, Massachusetts, September, 2001.

40. Tang, Q., Staub, C.M., Ding, W., Jin, Q., Wang, Z., and **Mulder, K.M.** km23: A novel TGF β signaling component that is truncated in human ovarian cancer. Penn State Univ., University Park, PA, April 2002.
41. Tang, Q., Staub, C.M., Gao, G., Jin, Q., Wang, Z., Ding, W., Aurigemma, R., and **Mulder, K.M.** km23: A novel TGF β receptor-interacting protein that is also a light chain of the motor protein dynein. Anti-Cancer Drug Discovery and Development Summit, Princeton, NJ, June 17-19, 2002.
42. **Mulder, K.M.** km23—A novel TGF-beta-related target that is altered in human cancers. Drug Discovery Technology, IBC Life Sciences, Boston, MA, August 3-8, 2002.
43. **Mulder, K.M.** km23: A novel target for the development of anti-cancer therapeutics and diagnostics. Protein-Protein Interaction, Newark, NJ, November 4-6, 2002.
44. **Mulder, K.M.** A novel TGF β receptor-interacting protein altered in human cancers that is also a light chain of the motor protein dynein. TGF β Superfamily: Roles in the Pathogenesis of Cancer and Other Diseases, La Jolla, CA, January 15-19, 2003.
45. Jin, Q., Ding, W., Staub, C.M., Gao, G., Tang, Q., and **Mulder, K.M.** A TGF- β receptor-interacting protein frequently mutated in epithelial ovarian cancer. AACR Annual Meeting, Washington, DC, July, 2003.
46. Q. Jin, M.D., W. Ding, M.D., Ph.D., C.M. Staub, G. Gao, M.D., and **K.M. Mulder, Ph.D.**, A novel Target for the Development of Anti-Cancer Diagnostics and Therapeutics. Innoventure 2003, Hershey, PA, May 2, 2003.